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ABSTRACT 
Sexual differentiation and the control of pubertal onset and development are complex 
processes whose disruption leads to the abnormal development of primary and/or 
secondary sexual characteristics and usually causes considerable stress for the 
individual. For example androgens, which signal through the androgen receptor (AR), 
are required for the correct development of both the internal and the external male sex 
organs. Mutations in the AR gene cause androgen insensitivity syndrome (AIS), which 
ranges in severity from complete (CAIS) to partial (PAIS) and to mild (MAIS) forms of 
androgen resistance. Patients with CAIS are genetically male but phenotypically female, 
demonstrating the importance of androgen action in sexual differentiation. Other genetic 
defects cause other variable forms of disorders of sex development (DSD).  
During puberty, the ability to reproduce sexually is achieved as sex organs and other 
sexual characteristics develop further into the mature, adult form. The onset of pubertal 
development is dependent on the reactivation of the hypothalamic-pituitary-gonadal 
(HPG) axis by increased secretion of gonadotropin-releasing hormone (GnRH) from the 
hypothalamus. Premature reactivation of this axis results in gonadotropin-dependent 
precocious puberty (GDPP), defined as the development of secondary sexual 
characteristics prior to eight years in girls and nine years in boys. On the other hand, in 
patients with congenital hypogonadotropic hypogonadism (CHH), the HPG axis fails to 
reactivate properly, leading to delayed, partial, or absent puberty. When a patient with 
CHH also has absent or defective sense of smell, the condition is called Kallmann 
syndrome (KS). The KS phenotype reflects the tightly connected development of GnRH 
neurons and the olfactory system. 
Although several genes are implicated in the disorders of puberty and sex development, 
the majority of the patients remain without a molecular genetic diagnosis. The aim of 
my thesis work was to identify genetic defects underlying disorders of sex development, 
specifically CAIS, and disorders of pubertal development, specifically CHH and GDPP, 
in Finnish and Danish patients.  
The genetic cause of CAIS in a family with two affected siblings and without mutations 
in the AR coding sequence or conserved splice sites was investigated by whole-genome 
sequencing and cDNA analysis. CAIS was found to be caused by a deep intronic AR 
mutation, which leads to the formation of two aberrantly spliced mRNA products and a 
significant reduction in the amount of normal AR mRNA and undetectable AR protein 
levels. This is the first reported pseudoexon-activating AR mutation that leads to CAIS. 
The genetic causes of both extremes of pubertal variation, GDPP and CHH, were 
investigated in Danish patients. Twenty-nine Danish girls with GDPP were screened for 
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mutations in MKRN3, a maternally imprinted gene recently identified as a regulator of 
pubertal onset. MKRN3 is expressed only from the paternal allele, and therefore, only 
paternally inherited MKRN3 mutations can cause precocious puberty. One paternally 
inherited mutation in MKRN3 was found in one of the screened girls with GDPP, and 
also in her brother who had early puberty.  
Forty-one Danish male patients with CHH were screened for mutations in the known 
CHH genes ANOS1, FGFR1, FGF8, PROK2, PROKR2, GNRHR, TAC3, TACR3, and 
KISS1R. Additionally, CDH7 was screened in two Danish CHH patients with hearing 
loss. In addition, fifty Finnish patients with CHH were screened for mutations in the 
CHH candidate genes SEMA3A and SEMA7A. Twelve out of forty-one of the Danish 
CHH patients got a molecular genetic diagnosis; four patients had a mutation in ANOS1, 
five in FGFR1, one had a homozygous mutation in GNRHR, and the two patients with 
hearing loss had a mutation in CHD7. Three heterozygous missense variants in SEMA3A 
were identified in three Finnish KS patients, two of which also had a previously 
identified mutation in FGFR1. Two heterozygous variants in SEMA7A were identified 
in one patient with normosmic HH and in one KS patient with a previously identified 
ANOS1 mutation.  
In conclusion, the intronic AR mutation is the first reported case of pseudoexon 
activation leading to AIS and demonstrates the importance of AR cDNA analysis in AIS 
patients who still lack a molecular genetic diagnosis. This study also produced new 
information on the genetic defects underlying the extreme ends of pubertal variation in 
Finland and Denmark. The results show that mutations in MKRN3 underlie precocious 
puberty in Danish patients, although the mutations are not very common in sporadic 
cases. FGFR1, ANOS1, CHD7, and GNRHR mutations were found to underlie CHH in 
the Danish patients, but the majority of them still remain without a molecular genetic 
diagnosis. Finally, mutations in SEMA3A and SEMA7A do not seem to contribute 
significantly to CHH, and it remains to be seen whether mutations in these two genes 
cause CHH in humans.  
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TIIVISTELMÄ 
Sukupuolten erilaistuminen ja murrosikäkehityksen käynnistyminen ja eteneminen ovat 
monimutkaisia tapahtumasarjoja, joiden häiriöt johtavat primaaristen ja/tai 
sekundaaristen sukupuoliominaisuuksien epätavalliseen kehitykseen aiheuttaen yleensä 
paljon huolta niistä kärsiville. Esimerkiksi androgeenireseptorin kautta signaloivat 
androgeenit ovat välttämättömiä miehen niin ulkoisten kuin sisäistenkin 
lisääntymiselinten kehitykselle. Mutaatiot androgeenireseptoria koodaavassa AR-
geenissä aiheuttavat androgeeniresistenssiä (androgen insensitivity syndrome, AIS), 
joka vaihtelee vakavuudeltaan täydellisestä (complete AIS eli CAIS) osittaiseen (partial 
AIS eli PAIS) ja edelleen lievään (mild AIS eli MAIS) androgeeniresistenssiin. CAIS-
potilaat ovat geneettisesti miehiä mutta ilmiasultaan naisia, mikä osoittaa androgeenien 
tärkeän roolin sukupuolten erilaistumisessa. Virheet muissa geeneissä voivat aiheuttaa 
muita vaihtelevia sukupuolisen kehityksen häiriöitä. 
Sukukypsyys saavutetaan murrosiässä sukupuolielimien ja toissijaisten 
sukupuoliominaisuuksien kehittyessä edelleen aikuiseen muotoonsa. 
Murrosikäkehityksen käynnistyminen on riippuvainen hypotalamus-aivolisäke-
sukupuolirauhanen-akselin (hypothalamic-pituitary-gonadal axis, HPG axis) 
uudelleenaktivoitumisesta. Uudelleenaktivoituminen tapahtuu gonadotropiineja 
vapauttavan hormonin (GnRH) erityksen lisääntyessä hypotalamuksesta. Akselin 
ennenaikainen aktivoituminen johtaa hypotalamuksen toiminnasta johtuvaan 
ennenaikaiseen murrosikäkehitykseen (gonadotropin-dependent precocious puberty, 
GDPP), mikä tarkoittaa sekundaaristen sukupuoliominaisuuksien kehittymistä tytöillä 
ennen kahdeksan ja pojilla ennen yhdeksän vuoden ikää. Toisaalta potilailla, joilla on 
synnynnäinen hypogonadotrooppinen hypogonadismi (CHH), HPG-akseli ei aktivoidu 
kunnolla, minkä seurauksena on viivästynyt, puuttuva tai osittainen murrosikäkehitys. 
Jos potilaalla on CHH:n lisäksi puuttuva tai vajavainen hajuaisti, hänellä sanotaan olevan 
Kallmannin oireyhtymä (KS). Tämä yhdistelmä on seurausta GnRH:ta tuottavien 
neuronien ja hajujärjestelmän tiivisti yhteen kytkeytyneestä kehityksestä.  
Vaikka sukupuolisen kehityksen ja murrosikäkehityksen häiriöihin on liitetty lukuisia 
geenejä, valtaosa näistä häiriöistä kärsivistä potilaista on edelleen vailla 
molekyyligeneettistä diagnoosia. Tämän väitöskirjatyön tavoitteena oli löytää uusia 
sukupuolen kehityksen ja murrosikäkehityksen häiriöitä aiheuttavia geenivirheitä. 
Työssä keskityttiin erityisesti androgeeniresistenssin, ennenaikaisen murrosiän ja 
synnynnäisen hypogonadotrooppisen hypogonadismin taustalla oleviin geenivirheisiin.  
Täydellisen androgeeniresistenssin syytä tutkittiin perheestä, jossa oli kaksi 
androgeeniresistenttiä sisarusta, joilla ei ollut mutaatioita AR-geenin koodaavalla 
alueella eikä geenin konservoituneissa silmukointikohdissa. Geenivirheen selvityksessä 
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käytettiin avuksi kokogenomisekvensointia ja AR-geenin cDNA-analyysia. 
Androgeeniresistenssin aiheuttajaksi paljastui syvällä AR-geenin intronissa sijaitseva 
virhe, joka johti kahden epätavallisen lähetti-RNA:n syntyyn ja normaalin lähetti-RNA:n 
määrän huomattavaan vähenemiseen, minkä seurauksena myös AR-proteiinin määrä oli 
havaitsemattoman alhainen. Tämä geenivirhe on ensimmäinen CAIS-potilailla 
raportoitu pseudoeksonin aktivoitumiseen johtava mutaatio AR-geenissä. 
Tanskalaisista potilaista tutkittiin murrosiän ajoituksen kahden ääripään taustalla olevia 
geneettisiä syitä. Kahdeltakymmeneltäyhdeksältä tanskalaiselta tytöltä, joilla oli 
ennenaikainen murrosikä, seulottiin MKRN3-geeni, joka on hiljattain tunnistettu 
murrosiän alkua säätelevä geeni. MKRN3-geenin äidiltä peritty kopio on hiljennetty, eli 
vain isältä perityt MKRN3-mutaatiot ilmentyvät ja voivat aiheuttaa ennenaikaisen 
murrosiän. Yhdeltä seulotuista tytöistä löytyi isältä peritty geenivirhe MKRN3-geenistä. 
Sama virhe löytyi myös tytön veljeltä, jolla oli aikainen murrosikä. 
Neljältäkymmeneltäyhdeltä tanskalaiselta CHH-potilaalta seulottiin tunnetut CHH-
geenit ANOS1, FGFR1, FGF8, PROK2, PROKR2, GNRHR, TAC3, TACR3 ja KISS1R. 
CHD7-geeni seulottiin kahdelta potilaalta, joilla oli kuulonalenema. Lisäksi 
viideltäkymmeneltä suomalaiselta CHH-potilaalta seulottiin CHH:n kandidaattigeenit 
SEMA3A ja SEMA7A. Kaksitoista tanskalaista potilasta sai molekyyligeneettisen 
diagnoosin; neljällä oli mutaatio ANOS1-geenissä, viidellä FGFR1-geenissä, yhdellä oli 
homotsygoottinen mutaatio GNRHR-geenissä, ja molemmilla kuulonalenemasta 
kärsivillä potilailla oli mutaatio CHD7-geenissä. SEMA3A-geenistä löytyi kolme 
heterotsygoottista geenivirhettä kolmelta suomalaiselta KS-potilaalta, joista kahdella oli 
myös aiemmin löydetty mutaatio FGFR1-geenissä. Kaksi SEMA7A-geenin virhettä 
löydettiin yhdeltä CHH-potilaalta, jolla oli normaali hajuaisti sekä yhdeltä KS-potilaalta, 
jolla oli jo aiemmin tunnistettu mutaatio ANOS1-geenissä.  
Yhteenvetona totean, että tässä työssä löytynyt ensimmäinen raportoitu AR-geenin 
pseudoeksonin aktivoitumiseen johtava introninen mutaatio on osoitus siitä, että AR:n 
cDNA-analyysi voi johtaa taudin molekyyligeneettisen syyn löytymiseen ilman 
geneettistä diagnoosia jääneillä AIS-potilailla. Lisäksi murrosiän häiriöiden 
geenivirheistä Suomessa ja Tanskassa saatiin uutta tietoa. Tulokset osoittavat, että 
virheet MKRN3-geenissä aiheuttavat ennenaikaista murrosikää tanskalaisissa potilaissa, 
joskin mutaatiot eivät ole kovin yleisiä sporadisissa tapauksissa. Tanskalaisilta CHH-
potilailta löytyi mutaatioita FGFR1-, ANOS1-, CHD7-, ja GNRHR-geeneistä, mutta 
valtaosa jäi vaille molekyyligeneettistä diagnoosia. Lopuksi totean, että mutaatiot 
SEMA3A- ja SEMA7A-geeneissä eivät näytä olevan merkittävä CHH:n aiheuttaja, ja 
nähtäväksi jää, aiheuttavatko mutaatiot näissä kahdessa geenissä ylipäätään CHH:ta 
ihmisillä.  
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1. INTRODUCTION 
The continuation of human reproduction is dependent on the correct formation of two 
distinct sexes and the subsequent full maturation of the reproductive system in each 
generation. The phenotypic differences between the two sexes are formed through 
processes called sex determination and sex differentiation during embryonic 
development. In mammals, the presence of the SRY locus in the genome sets in motion 
a series of events that leads to the development of the testes, which in turn secrete 
hormones that guide the differentiation of the internal and external sex organs towards 
the male phenotype (Biason-Lauber 2010). The capacity to reproduce sexually is 
achieved during puberty when the sex organs and secondary sexual characteristics 
develop into the mature form. The onset of pubertal development is dependent on the 
reactivation of the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamic 
gonadotropin-releasing hormone (GnRH)-secreting neurons begin to secrete GnRH with 
increased frequency at the onset of puberty. The increased pulsatile secretion of GnRH 
leads to the secretion of the gonadotropins luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) from the anterior pituitary, which in turn stimulates the 
formation of gametes and the secretion of sex steroids from the gonads.  
Disorders of sex development (DSD) is a broad term for conditions in which sex 
differentiation or development is atypical. DSDs are usually detected in early childhood 
due to ambiguous genitalia in the infant, but may also escape detection until adolescence 
or early adulthood (Hiort et al. 2014), when the first presenting sign may be absent 
pubertal development, or primary amenorrhea in a female adolescent who has already 
commenced breast development and has a pubertal growth spurt (Hughes et al. 
2012).One example of the latter case is complete androgen insensitivity syndrome 
(CAIS), in which a loss-of-function mutation in the androgen receptor gene, AR, leads 
to a female appearance in a genetically male (46,XY) individual (Hughes et al. 2012). 
Not all patients with CAIS are found to have a mutation in AR (Jääskeläinen 2012), 
suggesting some mutations in regulatory and other non-coding regions of AR may go 
undetected in these patients.  
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Another reason for atypical pubertal development are disorders where the normal timing 
of puberty is disrupted, such as in gonadotropin-dependent precocious puberty (GDPP) 
or congenital hypogonadotropic hypogonadism (CHH). GDPP results from the 
premature reactivation of the HPG axis when GnRH secretion is stimulated or inhibition 
of GnRH secretion is terminated prematurely, leading to the development of secondary 
sexual characteristics prior to the age of 8 years in girls or 9 years in boys (Parent et al. 
2003). CHH is a rare disorder characterized by absent, delayed or partial puberty that is 
caused by defects in the development of the hypothalamic GnRH neuron population or 
defective GnRH secretion or signaling (Kim 2015).  CHH presents sometimes as a part 
of a syndrome, such as Kallmann syndrome (KS), where patients with CHH also have 
an absent or defective sense of smell. The combination of absent puberty and defective 
sense of smell is explained by the tightly connected development of the GnRH neurons 
and the olfactory system (Forni & Wray 2015).  
It is estimated that, in the general population, 50-80% of the variation in the timing of 
puberty is dependent on genetic factors (Gajdos et al. 2010). However, the genetic basis 
for the control of pubertal onset remains largely unresolved. The development of the 
GnRH-secreting neurons is also still not fully understood. The identification of genetic 
defects underlying the extreme ends of pubertal timing reveals new factors that control 
these critical processes. The molecular genetic causes of GDPP, however, have remained 
largely a mystery until the recent discovery of mutations in MKRN3, which seems to 
have an important function in preventing the premature reactivation of the HPG axis in 
the prepubertal period (Abreu et al. 2013). Additionally, the rarity and the clinical and 
genetic heterogeneity of CHH make it difficult to study with traditional genetics methods 
(Cadman et al. 2007). Several genes have already been connected with the disorder; 
however, in about 50% of the cases, the molecular genetic cause remains unresolved 
(Kim 2015). The clinical and molecular genetic features of Finnish patients with KS or 
normosmic HH have been described previously (Laitinen et al. 2011, Laitinen et al. 
2012), with 44% of KS patients getting a molecular genetic diagnosis. The high 
proportion of patients still lacking an identified genetic cause implies that there are more 
genes whose mutations underlie the disorder in Finland and in other populations.  
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The aim of this thesis work was to identify genetic causes of disorders where the normal 
development of sex and puberty is disrupted, focusing on CAIS, GDPP, KS, and 
normosmic CHH.  
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2. REVIEW OF THE LITERATURE 
2.1 Sex determination and sex differentiation 
2.1.1 Sex determination 
During the first weeks of life, embryos of the different sexes are indistinguishable but 
for their genetic makeup. Development of the different sexes can be divided into two 
phases; the first phase is sex determination, during which the bipotential gonads develop 
into testes or ovaries; the second phase is sex differentiation, during which the gonads 
guide the development of the phenotypical sex by secreting hormones (Biason-Lauber 
2010). The bipotential gonads develop around gestational week 6 in humans, and 
differentiate between weeks 6 and 10 guided by the genetic architecture. In mammals, 
sex is determined by the sex chromosomes X and Y. The default developmental program 
is the female developmental pattern, which is suppressed when the embryo carries a Y 
chromosome, or more specifically, the SRY (sex-determining region on the Y 
chromosome) locus (Biason-Lauber 2010). Steroidogenic factor 1 (SF-1) is expressed in 
the bipotential gonad, where it activates the key testis-development-promoting gene 
SOX9 (SRY-box 9) expression and, if present, SRY expression (Figure 1) (Knarston et 
al. 2016). SRY and SF-1 act together to upregulate the expression of SOX9, which in 
turn guides the development of Sertoli cells and thus testis differentiation. Other factors 
that regulate SOX9 expression include FGF9, prostaglandin D2, DAX1, CBX2, WT1, 
GATA4, and FOG2 (Knarston et al. 2016). In the absence of SRY, the expression of 
SOX9 remains low and the gonad develops into an ovary. The main signaling pathway 
directing ovarian development is the WNT/?-catenin pathway. Wingless-type MMTV 
integration site family member 4 (WNT4) and R-spondin family member 1 (RSPO1) are 
positive effectors of ?-catenin that are both essential for ovarian development (Knarston 
et al. 2016). The WNT/?-catenin and SRY/SOX9 signaling pathways repress each other 
during development, but the repression of the wrong signaling pathway is important even 
in adulthood to maintain the gonadal identity (Knarston et al. 2016). FOXL2 helps 
maintain ovarian identity by suppressing SOX9, DMRT1, and other male-specific 
factors, whereas DMRT1 maintains the identity of the testis by suppressing FOXL2 and 
retinoic acid signaling (Knarston et al. 2016). 
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Figure 1. Factors guiding sex determination. WT1 (Wilms tumor 1) and SF1 are expressed in 
the bipotential gonads, where they induce the expression of SOX9, and SRY, if present. CBX2 
promotes the expression of SF1 directly and possibly through the inhibition of DAX1. SF1 and 
SRY act together to increase SOX9 expression, which is then maintained through a positive 
autoregulatory loop. SOX9 expression also initiates feedforward loops through FGF9 and 
prostaglandin D2 (PGD2) signaling. SOX9 promotes Sertoli cell development and represses the 
β-catenin pathway. When SOX9 expression is low, β-catenin levels rise in response to RSPO1 
and WNT4, which shuts down SOX9 expression. FOXL2 helps maintain ovarian identity by 
repressing male-specific factors. Reprinted from Best Practice & Research Clinical 
Endocrinology & Metabolism, 24, Anna Biason-Lauber, Control of sex development, 163-186, 
Copyright (2010), with permission from Elsevier. 
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2.1.2 Sex differentiation 
In human development, the reproductive ducts are undifferentiated at weeks 6-7 of 
gestation, and both sexes have both mesonephric (Wolffian) and paramesonephric 
(Müllerian) ducts. The differentiation of these ducts is guided by the hormones secreted 
by the differentiated gonads from around 7 weeks of gestation onwards (Biason-Lauber 
2010). In males, the Wolffian ducts develop into epididymis, vas deferens, and the 
prostate and the Müllerian ducts regress, whereas in females, the Müllerian ducts 
develop into the fallopian tubes, the uterus, and the upper third of the vagina, and the 
Wolffian ducts regress (Figure 2) (Biason-Lauber 2010).  
In Sertoli cells of the testis, SF-1 activates the expression of antimüllerian hormone 
(AMH), which causes the regression of the Müllerian ducts. In Leydig cells, SF-1 
promotes the expression of androgens, which promote the development of the Wolffian 
ducts into the male reproductive ducts and the development of the external male genitalia 
(Figure 2). The testes synthesize testosterone, some of which is metabolized by 5?-
reductase type 2 into the more potent dihydrotestosterone (DHT). DHT is required for 
labioscrotal fusion between the 8th and 12th gestational weeks, and for the growth of the 
phallus especially in the third trimester; in other words, it is necessary for the 
development of the external male genitalia, although the internal male genitalia develop 
normally even in the absence of DHT (Auchus & Chang 2010, Mendonca et al. 2010). 
In the absence of androgens or androgen action, the Wolffian ducts regress and the 
external genitalia become female.  
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Figure 2. The differentiation of the male and female reproductive ducts. Antimüllerian 
hormone (AMH), which is secreted from the testis, causes the regression of the Müllerian ducts, 
and testosterone (T) promotes the development of the Wolffian ducts into epididymis, vas 
deferens, and the prostate. In the absence of AMH and testosterone, the Müllerian ducts develop 
into the fallopian tubes, the uterus, and the upper third of the vagina, and the Wolffian ducts 
regress. Reprinted by permission from Macmillan Publishers Ltd: [Nature Medicine] (Martin M 
Matzuk & Dolores J Lamb. The biology of infertility: research advances and clinical challenges. 
14:1197-213), copyright (2008). 
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2.2 Disorders of sex development 
2.2.1 46,XY and 46,XX disorders of sex development 
Disorders of sex development (DSDs) are defined as ”congenital conditions in which the 
development of chromosomal, gonadal, or anatomical sex is atypical” (Hughes et al. 
2006). DSDs can be either disorders of sex determination or sex differentiation; the 
former are typically caused by defects in transcription factors that guide gonadal 
development and the latter by defects in hormones and hormone receptors that are 
involved in the development of the phenotypical sex (Biason-Lauber 2010). The 
biological classification of different forms of DSDs is presented in table 1 (Hiort et al. 
2014). 
The identification of gene defects underlying different forms of DSDs has been 
invaluable for the identification of the different factors involved in sex determination 
and differentiation. For example, mutations in SRY, SOX9, NR5A1 (encoding SF-1), 
GATA4, DMRT1, DHH, CBX2, and MAP3K1 have been identified in individuals with 
46,XY disorders of primary sex determination (46,XY complete or partial gonadal 
dysgenesis) (Bashamboo & McElreavey 2015). 46,XX testicular DSDs and ovotesticular 
DSDs, in which the gonads are either completely or partially comprised of testicular 
tissue in an 46,XX individual, are caused by gain-of-function mutations affecting testis-
determining genes or loss-of-function mutations in the female pathway genes (Knarston 
et al. 2016). 46,XX testicular DSD is in 90% of the cases caused by the translocation of 
the SRY locus into one of the X chromosomes (Knarston et al. 2016). The second most 
common cause is the duplication of the SOX9 gene or its promoter region, with additional 
rare cases caused by the duplication of SOX3, SOX10, or FGF9, or a loss-of-function 
mutation in RSPO1 or WNT4 (Knarston et al. 2016). The majority of the 46,XX 
ovotesticular DSD cases have an unknown molecular genetic cause, although similar 
SRY, SOX9, RSPO1, and WNT4 mutations as in 46,XX testicular DSD have been 
identified in a subset of patients (Knarston et al. 2016).  
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Table 1. The biological classification of DSDs (table based on Hiort et al. 2014). 
Classification 
based on 
karyotype   
  
Examples of mutated genes 
46,XX 
Disorders of 
gonadal 
development 
Ovotesticular DSD  
Testicular DSD Translocation of SRY;  duplication of FGF9 or SOX9 
Syndromic forms  
Disorders of 
androgen excess 
Congenital adrenal 
hyperplasia (CAH) CYP21A2, CYP11B1, HSD3B2 
Aromatase deficiency CYP19A1 
Luteoma  
Latrogenic  
Unclassified 
disoders 
Mayer-Rokitansky-Küster-
Hauser syndrome LHX1, TBX6 
Complex syndromic 
disorders 
 
46,XY 
Disorders of 
gonadal 
development 
Ovotesticular DSD  
Monogenic complete or 
partial gonadal dysgenesis SRY, WT1, MAP3K1, NR5A1 
Syndromic forms  
Disorders of 
androgen 
synthesis 
Syndromic (e.g. Smith-
Lemli-Opitz syndrome) DHCR7 
CAH and early androgen 
biosynthesis defects 
CYP11A1, STAR,  
HSD3B1, CYP17A1 
Androgen biosynthesis 
defects SRD5A2, HSD17B3 
Endocrine disruption  
Disorders of 
androgen action 
Complete and partial 
androgen insensitivity AR 
Unclassified 
disorders 
Hypospadias with unknown 
genetic cause 
 
Epispadias  
Complex syndromic 
disorders 
 
Chromosomal 
DSDs 
45,X (Turner syndrome and variants) 
45X/46,XY (mixed gonadal dysgenesis) 
47,XXY (Klinefelter syndrome and variants) 
Other complex chromosomal rearrengements 
CYP21A2 encodes 21-hydroxylase; CYP11B1 encodes 11-beta-hydroxylase; HSD3B3 encodes hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid delta-isomerase 2 (3β-HSDII); CYP19A1 encodes aromatase; DHCR7 encodes  7-
dehydrocholesterol reductase; CYP11A1 encodes the cholesterol side-chain cleavage enzyme P450scc; STAR encodes the 
steroidogenic acute regulatory protein; HSD3B1 encodes Hydroxy-Delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 (3β-HSDI); SRD5A2 encodes steroid 5 alpha-reductase 1; HSD17B3 encodes 17-beta hydroxysteroid 
dehydrogenase 3.
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Virilization of the female fetus is a form of 46,XX disorders of sex differentiation caused 
by excess DHT or foreign androgens during the critical period of gestation when sex 
differentiation occurs, whereas 46,XY disorders of sex differentiation are commonly 
caused by defects in androgen production, metabolism, or action (Auchus & Chang 
2010, Mendonca et al. 2010). Excess androgens in female fetuses are most commonly 
derived from the adrenal glands, where a mutation in one of the enzymes involved in 
steroidogenesis can lead to the diversion of cortisol precursors to other steroid hormones. 
This disorder is a form of congenital adrenal hyperplasia (CAH), which may lead to early 
death due to dehydration if left untreated when mineralocorticoid biosynthesis is also 
affected (Auchus & Chang 2010). Rarely, excess androgens may be the result of 
aromatase deficiency, i.e. the aromatase enzyme that converts the high levels of fetal 
adrenal androgens to estrogens does not function properly, which also leads to impaired 
estrogen production by the ovaries and peripheral tissues and the failed development of 
female secondary sexual characteristics later in life (Auchus & Chang 2010). The excess 
androgens may also be of maternal origin, usually due to androgen-producing tumors 
(Auchus & Chang 2010). 46,XY disorders of sex differentiation may also present as a 
part of CAH if an enzyme participating in both adrenal and testicular steroidogenesis is 
affected, or it may be caused by mutations in enzymes involved only in testicular 
steroidogenesis, such as in 17?-hydroxysteroid dehydrogenase (HSD) type III deficiency 
(Mendonca et al. 2010). 5?-reductase type 2 deficiency causes a defect in testosterone 
metabolism, so that sufficient DHT for the development of the external male genitalia is 
lacking, which results in ambiguous, female-like external genitalia (Mendonca et al. 
2010). Defects in androgen signaling are caused by mutations in the androgen receptor 
gene, leading to androgen resistance, which is discussed in more detail in the next section 
(2.1.4). Mutations in the genes encoding AMH and its specific receptor, AMHR-II, in 
turn cause persistent Müllerian duct syndrome, in which 46,XY individuals are 
otherwise normally virilized and clearly identified as males at birth, but have Müllerian 
derivatives (uterus and fallopian tubes) that the testes are tightly attached to, causing 
cryptorchidism and low fertility (Josso et al. 2005). 
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2.2.2 Androgen insensitivity syndrome (AIS) 
The most common known cause of 46,XY DSDs is androgen insensitivity syndrome 
(AIS), which is caused by mutations in AR, the X-linked gene encoding the androgen 
receptor. There are over 500 CAIS-causing mutations in the Androgen Receptor Gene 
Mutations Database (Gottlieb et al. 2012) ranging in severity from completely abolished 
to mildly impaired AR function, which is reflected in the severity of the phenotype. 
Patients with complete AIS (CAIS), although genetically male (46,XY), are 
phenotypically female; they have estrogen-dependent secondary sexual characteristics 
because of peripheral aromatization of androgens, little or no pubic axillary hair and a 
blind-ending vagina (Hughes et al. 2012). The gonads are testes, but the reproductive 
ducts fail to develop normally because of the lack of androgen action. The structures that 
develop from the Müllerian ducts are also missing because of the action of antimüllerian 
hormone. The typical phenotype in partial AIS (PAIS) is a micropenis, perineoscrotal 
hypospadias, and a bifid scrotum, although the phenotype can range from mostly male 
to mostly female (Hughes et al. 2012). Mild AIS presents as infertility without associated 
genital anomalies. An AR mutation has been identified in 80 to 100% of CAIS patients 
(Jääskeläinen 2012), but the percentage is much lower, 28-73% (Jääskeläinen 2012), or 
even as low as 16% (Audi et al. 2010), in PAIS patients. The milder forms of androgen 
resistance have phenotypic overlap with some other 46,XY DSDs, such as 5?-reductase 
and 17?-HSD3 deficiencies (Mendonca et al. 2010), and therefore, the identification of 
the causal mutation is important for a confirmed diagnosis of the disorder (Hughes et al. 
2012). The failure to identify an underlying AR mutation in some CAIS patients suggests 
that mutations in some obligate AR co-factors may cause the disorder in some cases 
(Adachi et al. 2000), although such mutations have not yet been reported (Jääskeläinen 
2012). Alternatively, AIS may be caused by mutations in the introns or regulatory 
regions of AR that are more difficult to recognize. 
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2.3 The hypothalamic-pituitary-gonadal axis 
The hypothalamic-pituitary-gonadal (HPG) axis is responsible for the acquirement and 
maintenance of reproductive capacity. The hypothalamic gonadotropin-releasing 
hormone (GnRH) -secreting neurons have a key role in the function of the HPG axis. 
Mammals have 1000-3000 GnRH neurons that are located as a dispersed continuum 
from the olfactory bulbs to the medial septal nuclei, preoptic area, anterior hypothalamic 
area, and mediobasal hypothalamus (Herbison 2014). At least in mice, most GnRH 
neurons have long projections called dendrons (a combination of an axon and a dendrite) 
that project into the median eminence (ME), where they release GnRH into the pituitary 
portal blood vessels (Herde et al. 2013). GnRH then reaches the anterior pituitary, where 
it stimulates the gonadotropes to secrete the gonadotropins luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH). The gonadotropins are transported in the 
circulation and target cells in the testes and the ovaries. In males, LH targets the Leydig 
cells and promotes testosterone production, whereas FSH targets the Sertoli cells where 
it promotes the synthesis of growth factors that promote spermatogenesis and other 
factors important for the function of the testis (Smith & Walker 2014). FSH also 
promotes the synthesis of inhibins in the testes, where they act locally as growth factors, 
and, through endocrine signaling, exert a negative feedback on FSH secretion at the level 
of the anterior pituitary (De Kretser et al. 2000). Androgens, which are aromatized into 
estrogens in the brain, exert a negative feedback on the secretion of GnRH, LH, and FSH 
at the level of the hypothalamus and the anterior pituitary (Clarke et al. 2012). In females, 
FSH promotes the maturation of ovarian follicles to the preovulatory stage, and LH 
promotes ovulation (Hunzicker-Dunn & Mayo 2015). After ovulation, LH acts on the 
cells that form the corpus luteum and promotes progesterone production. FSH also 
stimulates inhibin synthesis in the granulosa cells (Hunzicker-Dunn & Mayo 2015). The 
ovarian cells produce estrogens and progestins, which exert either a positive or a 
negative feedback on the hypothalamus and the pituitary; during most of the menstrual 
cycle, the feedback is negative, but it changes to positive just before ovulation and 
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induces the ovulatory LH surge (Clarke et al. 2012). The HPG axis is depicted in figure 
3. 
 
 
Figure 3. The hypothalamic-pituitary-gonadal (HPG) axis. GnRH is released from the 
hypothalamus into the pituitary portal vessels. In the pituitary, GnRH stimulates the secretion of 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are transported in the 
circulation to their target cells in the testes and ovaries, where they promote the synthesis of sex 
steroids. The sex steroids in return exert either a negative or a positive feedback on the 
hypothalamus and the pituitary (Clarke et al. 2012). 
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2.4 The development, migration and control of GnRH neurons 
GnRH neurons originate outside the brain. GnRH expression is first detected in the nose, 
in the olfactory placode, around gestational day 10 in the mouse (Schwanzel-Fukuda & 
Pfaff 1989, Wray et al. 1989b). From there the GnRH neurons migrate into the brain 
during prenatal development along the axons of the olfactory system (Figure 4) 
(Schwanzel-Fukuda & Pfaff 1989, Wray et al. 1989a, Schwanzel-Fukuda et al. 1996). 
The origin of GnRH neurons is still under debate, with some evidence suggesting that 
some of the cells might actually be derived from the neural crest at least in mice, which 
could partly explain the heterogeneity of the cells (Forni et al. 2011). In mouse and 
chicken embryos, neural crest was also identified to be the source of the olfactory 
ensheathing cells (OECs), which are glial cells that sheath olfactory axons in the same 
way as nonmyelinating Schwann cells surround other axons of the peripheral nervous 
system (Barraud et al. 2010). OECs leave the olfactory placode around gestational day 
10 in mice, a little before GnRH neurons begin their migratory journey toward the brain 
(Geller et al. 2013). They form a microenvironment for migrating GnRH neurons, and 
appear to be crucial for successful migration (Barraud et al. 2013, Pingault et al. 2013, 
Geller et al. 2013). The correct development and migration of GnRH neurons are 
dependent on the interplay of multiple factors that regulate craniofacial development, 
development of the neural crest and the OECs, growth and guidance of the olfactory 
axons, and neurogenesis, adhesion and migration of the GnRH neurons themselves 
(Forni & Wray 2015). Defects in any of these processes can lead to impaired 
reproductive capacity in combination with other developmental abnormalities. The 
recently developed protocol for GnRH-neuron differentiation from stem cells will 
potentially reveal previously unknown processes involved in GnRH neuron development 
and function (Lund et al. 2016). 
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Figure 4. Schematic drawing of the migratory journey of GnRH neurons. GnRH neurons 
migrate from the olfactory placode to the hypothalamus along the axons of the olfactory system. 
 
GnRH neurons release GnRH in a pulsatile fashion, which is critical for the secretion of 
the gonadotropins, since continuous GnRH release has an opposite, inhibitory effect on 
their secretion from the pituitary (Belchetz et al. 1978). The neurons receive inputs from 
several parts of the central nervous system to regulate the secretion of GnRH. The long 
dendrons of GnRH neurons receive synaptic inputs along their entire length, including 
in the proximity of the ME, which suggests the capability to fine tune neurosecretion 
(Herde et al. 2013). The dendrons of different neurons also come into close proximity to 
one another and even share synapses from afferent axon terminals at the sites where they 
bundle together, which may be a means of synchronization of the dispersed GnRH 
neuron population (Campbell et al. 2009). There are also dynamic changes in the GnRH 
dendron trajectories to the ME, for example during the different phases of the estrous 
cycle, and there appears to be a dynamic interaction between the nerve terminals, 
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neuroglial cells, and endothelial cells (Prevot et al. 2010). Special ependymoglial cells, 
called tanycytes, play a major role in controlling the accessibility of the GnRH neuron 
terminals to the ME, thus controlling the release of GnRH into the pituitary portal 
vessels, for example during the different phases of the estrous cycle (Prevot et al. 1999). 
Vascular endothelial cells may be involved in relaying signals, such as hormones, from 
the circulation to the GnRH neurons and the other cells surrounding them to ensure 
GnRH is synthesized and secreted effectively at the correct time (De Seranno et al. 
2010). 
Several neurotransmitters, such as GABA and glutamate, are known to regulate GnRH 
secretion, but the most potent activator of GnRH neurons identified to date is kisspeptin, 
which is mainly secreted by neurons located in two different brain regions, namely the 
preoptic area and the mediobasal hypothalamus (Herbison 2014). At least in rodents, the 
kisspeptin neuron population located in the preoptic area is bigger in females than in 
males and is thought to be involved in the activation of the GnRH neurons during the 
preovulatory LH surge (Kauffman et al. 2007). In humans, however, the effect of 
estradiol on the pituitary rather than on the kisspeptin neurons may be more important 
for creating the preovulatory surge (Herbison 2016). The other kisspeptin-producing 
neurons, located in the arcuate nucleus in the mediobasal hypothalamus, are called 
KNDy neurons because, in addition to kisspeptin, they also express neurokinin B (NKB) 
and dynorphin A, which are thought to autoregulate the KNDy neurons in a stimulatory 
(NKB) or an inhibitory (dynorphin A) manner (Navarro & Tena-Sempere 2012). The 
importance of NKB as a stimulator of kisspeptin release is seen in cases where loss-of-
function mutations either in the gene encoding NKB (TAC3) or its receptor (TACR3) 
cause CHH, as described later. The KNDy neurons are suggested to be involved in 
generating the pulsatility of GnRH secretion, in the negative feedback of estrogen on LH 
secretion, and in the onset of puberty (Herbison 2014). They may also be involved in 
relaying information on the metabolic status of the body to the GnRH neurons to ensure 
reproduction is only allowed when sufficient energy is available, although persistent 
overweight may also reduce Kiss1 expression (Navarro & Tena-Sempere 2012). 
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2.5 Current understanding on the factors controlling the onset of puberty 
The ability to reproduce sexually is achieved during puberty, when sex organs and other 
sexual characteristics develop into the adult form. Usually, the first sign of central 
puberty in girls is the onset of breast development from Tanner stage B1 (pre-adolescent) 
into B2 (breast bud stage) (Marshall & Tanner 1969), and in boys the enlargement of 
testis volume to at least 3 ml (Tanner stage G2) (Marshall & Tanner 1970, Ankarberg-
Lindgren & Norjavaara 2004). The onset of puberty is dependent on the reactivation of 
the HPG axis with the increased pulsatile secretion of GnRH from the hypothalamus, 
which occurs first during sleep and eventually also during the waking hours as puberty 
progresses. The HPG axis is also active during the first few months of life (known as 
minipuberty), when the activity seems to be important for the development of the Sertoli 
cells in boys (Waldhauser et al. 1981, Andersson et al. 1998), after which it remains 
quiescent until the onset of puberty.  
There is considerable variation, approximately 5 years, in the timing of puberty even 
among healthy individuals, owing to both genetic and environmental factors (Parent et 
al. 2003, Gajdos et al. 2010). According to the Copenhagen Puberty study, puberty onset 
occurs between the ages of 8 and 13 years in most girls, and between the ages of 9 and 
14 years in most boys (Aksglaede et al. 2009, Sørensen et al. 2010a). It is estimated that 
up to 50-80% of the variation in the timing of pubertal onset is explained by genetic 
factors, which is evidenced by the high correlation of the pubertal timing within ethnic 
groups, families, and monozygotic twins (Gajdos et al. 2010). Several genome-wide 
association studies have found that variation at an intergenic locus at 9q31.2 and at the 
6q21 locus at or near the LIN28B gene associate with age at menarche (Sulem et al. 2009, 
He et al. 2009, Ong et al. 2009, Perry et al. 2009), but they are estimated to explain only 
0.6% of the variation (He et al. 2009). Because of the complex interplay of multiple 
factors involved in puberty onset it is most likely impossible to pinpoint the direct 
influence of only one gene on the timing in the general population. Indeed, a more recent 
study suggested the involvement of at least hundreds of common variants in pubertal 
timing (Perry et al. 2014). Interestingly, the authors also found parent-of-origin-specific 
associations between variation at three imprinted loci, including the genes MKRN3, 
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DLK1, and KCNK9 and age at menarche, and implicated retinoic acid and GABAB 
receptor II signaling as novel regulators of pubertal timing (Perry et al. 2014). 
Epigenetic changes are also involved in the regulation of pubertal timing at least in 
female rats, where the epigenetic repression of two transcriptional silencers, Eed and 
Cbx7, is required for increased Kiss1 expression at the onset of puberty (Lomniczi et al. 
2013). In addition, microRNAs – miR-200 and miR155 in particular – were recently 
shown to be involved in the regulation of puberty onset and fertility in mice, where they 
negatively regulate factors that repress Gnrh expression either directly or indirectly 
(Messina et al. 2016). From these results it is apparent that the regulation of puberty 
onset involves a complex system including repressive and activating factors, epigenetic 
modulators and microRNAs, whose interplay finally leads to the increased pulsatility of 
GnRH secretion. A model has been proposed where an intrinsic developmental clock 
measures the overall growth, development, and composition of the body, and ensures 
that puberty is not initiated until sufficient maturity and the right body composition is 
reached, after which other factors are able to fine-tune the secretion of GnRH in response 
to environmental and peripheral signals (Sisk & Foster 2004). One factor that signals 
information on the body composition is leptin, a hormone produced by adipocytes, which 
provides the hypothalamus with information on fat mass and energy status of the body 
and is involved in the control of eating behavior. The importance of leptin signaling for 
puberty onset is especially seen in patients who have mutations in the genes encoding 
leptin, LEP, or its receptor, LEPR; these patients are morbidly obese and suffer from 
hypogonadotropic hypogonadism (Strobel et al. 1998, Clément et al. 1998). The 
influence of peripheral and environmental factors on puberty is also seen as the secular 
trend towards earlier puberty onset that occurred most prominently from the mid-1800s 
to the 1960s in the developed countries, most likely reflecting the influence of both 
improved nutrition and health care (De Muinck Keizer-Schrama & Mul 2001, Parent et 
al. 2003). In addition, endocrine-disrupting chemicals in the environment, acute and 
chronic illnesses, physical and psychological stressors, as well as the climate and the 
light-dark cycle are all known or suggested to modulate the reproductive axis and 
pubertal timing (Parent et al. 2003).  
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2.6 Gonadotropin-dependent precocious puberty (GDPP) 
2.6.1 Clinical manifestation of GDPP 
Precocious puberty is defined as the onset of breast development (Tanner B2 stage) 
before the age of 8 years in girls and as the onset of testicular development (Tanner stage 
G2) before the age of 9 years in boys (Parent et al. 2003). The recent trend towards earlier 
puberty onset has raised the question whether the age limits for precocious puberty 
should be lowered, but no consensus has been reached on the matter (Latronico et al. 
2016). Additionally, ethnicity needs to be taken into consideration, as for example 
African-American girls seem to have earlier puberty onset than white American girls 
(Herman-Giddens et al. 1997).  
Precocious puberty is usually caused by the premature increased pulsatile secretion of 
GnRH, and it is called gonadotropin-dependent precocious puberty (GDPP) or central 
precocious puberty, as opposed to peripheral (or gonadotropin-independent) precocious 
puberty (Latronico et al. 2016). GDPP can be caused by lesions in the central nervous 
system, such as a hypothalamic hamartoma, hydrocephalus, or a tumor, or it may be 
caused by endocrine disruptors, changes in the environment (e.g. international adoption), 
or certain genetic changes. GDPP is much more common in girls than in boys; there are 
15-20 times more girls with PP, and the most common causes of PP are also different 
between the sexes: 50-70% of boys with GDPP have a central nervous system lesion, 
whereas in girls, 90% of the cases are idiopathic (Latronico et al. 2016). The estimated 
incidence of GDPP is 1:5 000-10 000 in American girls (Partsch et al. 2002), and the 
prevalence is 1:500 in Danish girls (Teilmann et al. 2005). Most cases are sporadic, 
although familial cases also exist, and the mode of inheritance seems to be autosomal 
dominant with sex-dependent penetrance (de Vries et al. 2004). Few genetic causes of 
GDPP are known; for example some chromosomal abnormalities resulting in complex 
syndromes, and mutations in MKRN3, KISS1, and KISS1R, have been reported in GDPP 
patients (see section 2.6.2) (Latronico et al. 2016). 
Individuals with GDPP have progressive pubertal development, and they usually have 
an advanced bone age and accelerated growth velocity. The follow-up of puberty 
progression helps to distinguish individuals with GDPP from those who have common 
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variants of premature puberty, for example isolated premature breast development 
without other pubertal signs, or premature pubic or axillary hair development caused by 
increased levels of adrenal-derived androgens (Latronico et al. 2016). MRI of the central 
nervous system is important to determine whether the precocious puberty is due to a 
central nervous system lesion, which may have no other presenting symptoms (Partsch 
et al. 2002). Precocious puberty can have several health implications, such as shorter 
adult height, increased obesity risk, risk of estrogen-dependent cancer, cardiovascular 
disease, and type 2 diabetes, as well as adverse psychosocial outcomes (Latronico et al. 
2016). GDPP can be treated with GnRH agonist treatment, which leads to the 
desensitization of the pituitary to GnRH and the eventual inhibition of gonadotropin 
release after a short stimulation period (Partsch et al. 2002). The treatment should result 
in the regression or stabilization of pubertal symptoms, in lower growth velocity, and in 
slower advancement of bone age (Latronico et al. 2016).  
2.6.2 Molecular genetics of GDPP 
As mentioned above, the genetic basis of precocious puberty is poorly understood, 
although the existence of familial cases indicates a genetic cause in a subset of patients 
(de Vries et al. 2004). Candidate genes have been identified based on genetic linkage 
and/or function of the gene product; these candidates include KISS1, KISS1R, TAC3, 
TACR3, GNRHR, LIN28B, LIN28A, GABRA1, and NPY1R (Teles et al. 2011). 
LINA28B (HGNC ID: 32207) 
LIN28B encodes a human homolog of the C. elegans lin-28 gene. lin-28 is a 
heterochronic gene that controls the developmental timing of the C. elegans larvae; loss-
of function mutations of lin-28 lead to precocious development, whereas increased lin-
28 expression leads to a retarded phenotype (Moss et al. 1997). Lin-28 is an RNA-
binding protein that is expressed in human embryonic stem cells, and it specifically 
blocks the processing of the let-7 family miRNAs that control developmental timing 
(Viswanathan et al. 2008, Winter et al. 2009). Several GWA studies have found an 
association between variation at or near the LIN28B gene locus and the timing of puberty 
(Sulem et al. 2009, He et al. 2009, Ong et al. 2009, Perry et al. 2009) or height (Lettre et 
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al. 2008), but no causal LIN28B mutations have so far been reported in GDPP patients 
(Silveira-Neto et al. 2012, Tommiska et al. 2011) or in patients with constitutional delay 
of growth and puberty  (Tommiska et al. 2010). Additionally, both Lin28b and Lin28a, 
a functionally redundant homolog of Lin28b, affect growth and pubertal timing in mice 
in a sex-dependent manner (Corre et al. 2016). As LIN28A is also another candidate gene 
whose mutations may be involved in defective pubertal timing, it was screened in Danish 
girls with GDPP, but no mutations were found in this gene either (Tommiska et al. 2011). 
Thus, it may be that genetic variation in LIN28B, and possibly LIN28A, affects pubertal 
timing in the general population but is not at least a common cause of more extreme 
variants of pubertal timing (Corre et al. 2016).  
KISS1 (HGNC ID: 6341) and KISS1R (HGNC ID: 4510) 
As kisspeptin is an important regulator of GnRH secretion and inactivating mutations in 
KISS1 and KISS1R cause CHH, it seems reasonable that activating mutations in the same 
genes could cause precocious puberty. Indeed, a heterozygous activating KISS1R 
mutation that leads to a prolonged intracellular response to kisspeptin has been reported 
in a girl with GDPP (Teles et al. 2008). Another heterozygous mutation in KISS1 was 
reported in 2010 in a boy with GDPP; the mutant protein seems to be more resistant to 
degradation than the wild-type protein, although it has the same capacity to induce 
signaling through KISS1R as wild-type kisspeptin (Silveira et al. 2010). Only one other 
KISS1 variant was identified in the 83 GDPP patients screened in the same study; a 
homozygous missense variant that was found in two unrelated girls and which did not 
show any difference to the wild-type protein in the functional assays (Silveira et al. 
2010). Other polymorphisms have also been reported in KISS1 in girls and boys with 
GDPP, but their functional significance is not known (Rhie et al. 2014, Mazaheri et al. 
2015). Additionally, some KISS1R and KISS1 polymorphisms may be associated with 
timing of puberty in Chinese girls, although functional evidence on the effect of the 
polymorphisms is still lacking (Luan et al. 2007a, Luan et al. 2007b). Overall, KISS1 and 
KISS1R mutations seem to be a very rare cause of GDPP. 
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Other candidate genes 
In the same vein as activating mutations in KISS1 and KISS1R may cause GDPP, same 
kind of mutations in GNRHR, TAC3, or TACR3 might be expected to underlie the 
disorder. Other candidate genes based on the function of the gene product include 
GABRA1 and NPY1R (Teles et al. 2011). GABRA1 encodes the gamma-aminobutyric 
acid type A receptor alpha1 subunit, which is the main mediator of the inhibitory effects 
of GABA on GnRH neurons (Terasawa & Fernandez 2001). NPY1R encodes a receptor 
for neuropeptide Y, which inhibits GnRH release in prepubertal primates (Plant & 
Barker-Gibb 2004). Since both GABA and NPY exert inhibitory effects on GnRH 
release during the prepubertal period, loss-of-function mutations in their receptors might 
be expected to underlie GDPP (Plant & Parker-Gibb 2004, Teles et al. 2011). Conclusive 
mutations in any of these candidate genes, however, have not been reported in GDPP 
patients so far, implying these kinds of mutations, if they exist, are very rare (Teles et al. 
2011).  
MKRN3 (HGNC ID:7114) 
MKRN3, a maternally imprinted gene that is expressed only from the paternal allele, 
encodes Makorin RING finger 3 protein, which is a ubiquitously expressed, putative E3 
ubiquitin ligase (Jong et al. 1999). MKRN3 is located in the Prader–Willi syndrome 
critical region on chromosome 15, although its disruption does not seem to be required 
for the syndrome to develop (Kanber et al. 2009). In 2013, Abreu and colleagues 
identified paternally inherited mutations in MKRN3 to underlie GDPP (Abreu et al. 
2013), and these findings have since been supported by several studies in diverse 
populations, making MKRN3 mutations the most common identified genetic cause of 
GDPP to date (Macedo et al. 2014, Settas et al.  2014, Schreiner et al. 2014, de Vries et 
al. 2014, Lee et al. 2015, Simsek et al. 2016, Dimitrova-Mladenova et al. 2016). Based 
on the finding that the expression of MKRN3 decreases simultaneously with increased 
expression of Tac2 and Kiss1 in the mouse arcuate nucleus, and that most of the 
mutations –being ones that lead to a premature stop-codon–  were predicted to be loss-
of-function, Abreu et al. suggested that MKRN3 could act as a pubertal break (Abreu et 
al. 2013). The mechanism of action, however, still remains elusive. The median age of 
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puberty onset in girls with MKRN3 mutations is 6.0 and in boys 8.25, which suggests 
that the suppression of GnRH release occurs normally after mini-puberty in these 
patients, but is lost prematurely (Abreu et al. 2015). Therefore, the function of MKRN3 
as a GnRH suppressor seems to be critical especially right before puberty onset (Macedo 
et al. 2014). Recently, Hagen et al. (2015) found that circulating levels of MKRN3 
decreased prior to pubertal onset in healthy Danish girls, and that MKRN3 levels were 
lower in girls who matured early than in the healthy controls. Of note, some of the girls 
with GDPP had very low or undetectable MKRN3 levels (Hagen et al. 2015). A similar 
decrease in circulating MKRN3 levels at the onset of puberty has later been reported 
also in boys (Varimo et al. 2016a, Busch et al. 2016), but the levels do not differ between 
healthy men and men with CHH (Varimo et al. 2016b). The declining MKRN3 levels at 
the onset of puberty are in accordance with the current hypothesis that MKRN3 acts as 
a pubertal break. 
2.7 Delayed puberty: congenital hypogonadotropic hypogonadism and 
Kallmann syndrome  
2.7.1 Clinical presentation 
Delayed puberty is traditionally defined as the absence of breast development by the age 
of 13 years in girls and the absence of testicular development by the age of 14 years in 
boys (Sedlmeyer et al. 2002). In most cases, there is no underlying pathological 
condition, so the delay reflects a part of the normal, wide spectrum of pubertal timing, 
and puberty will start spontaneously in due course. This condition is called constitutional 
delay of growth and puberty (CDGP). Adolescents with CDGP tend to be short for their 
age and have delayed skeletal maturation (Boehm et al. 2015). In contrast, individuals 
with congenital hypogonadotropic hypogonadism (CHH) typically will not undergo 
spontaneous pubertal development even by the age of 18 years, although some may have 
partial pubertal development, and they grow steadily but lack a growth spurt (Boehm et 
al. 2015). 
CHH is caused by defective or absent GnRH secretion or action, which can result from 
the absence or reduced amount of hypothalamic GnRH neurons, insufficient secretion of 
GnRH, or the inability of GnRH to stimulate gonadotropin secretion from the pituitary 
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(Bianco & Kaiser 2009). Patients with CHH have low serum levels of testosterone (men) 
or estradiol (women) and low or normal serum levels of gonadotropins, whereas other 
pituitary functions are normal (Boehm et al. 2015). When making a CHH diagnosis it is 
important to confirm that the GnRH deficiency is permanent and not functional, i.e. 
caused by for example medication, another illness, or excessive stress, weight loss or 
exercise such as in the case of hypothalamic amenorrhea in women (Seminara et al. 
1998). Structural lesions of the hypothalamus or pituitary that can disturb hormone 
synthesis and secretion must also be ruled out by MRI (Seminara et al. 1998). 
CHH is most often diagnosed when puberty fails to occur, although sometimes, when 
the GnRH deficiency is severe, it can present already in infancy as a micropenis and/or 
as uni- or bilateral cryptorchidism. Female infants lack such specific clinical signs of 
CHH, but mini-puberty offers an opportunity to investigate reproductive hormone levels 
in both sexes if there is a family history of CHH, or if CHH is suspected based on the 
presence of micropenis or cryptorchidism (Boehm et al. 2015). On the other hand, in 
some cases, CHH is diagnosed in men who have undergone normal pubertal 
development but who later develop GnRH deficiency (adult-onset hypogonadotropic 
hypogonadism) (Nachtigall et al. 1997). Although the GnRH deficiency is usually 
permanent, approximately 10-15% of patients with CHH have a reversal of the 
phenotype after discontinuing hormone therapy, so that the patient’s own HPG axis is 
activated and the levels of reproductive hormones stay normal even after discontinuation 
of the hormone therapy (Raivio et al. 2007, Laitinen et al. 2012, Sidhoum et al. 2014, 
Dwyer et al. 2016). This may be due to the plasticity and maturation of the neuronal 
system responsible for GnRH secretion that occurs in response to the sex steroids given 
during therapy (Raivio et al. 2007). Some patients carrying milder and more common 
mutations may have a greater tendency for reversal, although reversal of the phenotype 
cannot be predicted solely based on the underlying genetic defect (Laitinen et al. 2012, 
Sidhoum et al. 2014). 
CHH can present as isolated or syndromic with variable non-reproductive anomalies. 
About 50% of CHH patients have a defective sense of smell (anosmia or hyposmia, 
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meaning completely or partially lacking sense of smell, respectively) with usually –
although not always– hypoplastic/aplastic olfactory bulbs (Boehm et al. 2015). These 
patients are said to have Kallmann syndrome (KS), named after Franz Josef Kallmann, 
a psychiatrist and geneticist who first suggested a genetic basis for this disorder 
(Kallmann et al. 1944) that had already been described in 1856 by Maestre de San Juan 
(Maestre de San Juan, A. 1856). As a distinction from patients with KS, those who have 
a normal sense of smell are said to have normosmic HH (nHH). In addition to 
anosmia/hyposmia, patients with CHH can also have other developmental abnormalities 
that reflect the underlying genetic defect, such as a cleft lip or palate, renal agenesis, 
missing teeth, hearing loss, or bimanual synkinesia. CHH can also be a part of other 
syndromes, such as combined pituitary hormone deficiency (CPHD), septo-optic 
dysplasia (SOD), CHARGE syndrome, Waardenburg syndrome, and Bardet-Biedl 
syndrome (Boehm et al. 2015), but this work is mainly focused on nonsyndromic HH 
and Kallmann syndrome.   
The incidence of CHH in different populations is estimated to be 1-10 per every 100 000 
births, and it is approximately five times more common in men than in women (Bianco 
& Kaiser 2009). The estimated minimal incidence of Kallmann syndrome in Finland is 
1:48 000; 1:30 000 in males and 1:125 000 in females (Laitinen et al. 2011). Possible 
explanations for the male predominance include sex-dependent penetrance of the 
underlying mutations due to higher susceptibility of the HPG axis to disturbances in boys 
and underdiagnosis of CHH in females (Laitinen et al. 2011). 
2.7.2 Molecular genetics of CHH 
CHH is genetically a very heterogeneous disorder with X-linked recessive, autosomal 
dominant, and autosomal recessive modes of inheritance, although most of the cases are 
sporadic (Quinton et al. 2001). Although originally considered a monogenic disorder, 
di- and oligogenic inheritance of CHH have also been suggested, which could partly 
explain the very variable penetrance of some CHH-causing mutations (Pitteloud et al. 
2007a, Sykiotis et al. 2010). Environmental and peripheral factors may also modulate 
the phenotype together with the genetic background (Mitchell et al. 2011). There are 
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already over 25 genes, mutations in which have been implicated in CHH, but still about 
50% of the patients remain without a molecular genetic diagnosis (Kim 2015), which 
suggests the involvement of as-yet-unidentified genes whose defects underlie the 
disorder. It may be that mutations in non-coding regulatory regions of the already 
identified genes also underlie CHH in some patients. The identification of new CHH 
genes has been complicated by the rarity and heterogeneity of CHH, the lack of large 
pedigrees that would permit linkage analysis, and also the possibility of variable 
penetrance of the mutations. Modern high-throughput sequencing techniques provide a 
valuable tool that may help to overcome some of these issues. 
Normosmic HH and KS are for the most part caused by mutations in different genes, 
although there is also some genetic overlap. nHH is typically caused by mutations that 
affect the regulation of GnRH secretion, GnRH signaling in the pituitary, or GnRH itself, 
whereas KS is caused by mutations that disrupt the development of the olfactory system 
along with the development and/or migration of the GnRH neurons (Figure 5) (Kim 
2015). Genes that have so far been implicated in CHH are listed in table 2. 
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Figure 5. Genes, whose mutations have been implicated in CHH, grouped according to their 
known/hypothesized function (see main text for references). Note that CHH can also present 
as a part of combined pituitary hormone deficiency due to defects in other genes involved in 
pituitary development, which are not presented here.
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2.7.3 Genetic defects underlying Kallmann syndrome 
ANOS1 (previously known as KAL1, HGNC ID: 6211) 
ANOS1 (previously known as KAL1) is an X-linked gene that encodes anosmin-1, which 
is an extracellular matrix protein that binds to the cell membrane via heparan-sulfate 
proteoglycans (HSPG) (Soussi-Yanicostas et al. 1996). Anosmin-1 stimulates axonal 
growth and branching and acts as an axonal guidance molecule (Bülow et al. 2002, 
Soussi-Yanicostas et al. 2002). It is expressed in the developing olfactory bulbs and 
kidneys (Hardelln et al. 1999), and has the ability to exert a chemotactic effect on 
immortalized immature GnRH neurons (Cariboni et al. 2004). Findings in two fetuses, 
one of which had a deletion of ANOS1 and the other a mutation causing a premature 
stop-codon in the gene, demonstrated the importance of anosmin-1 in the development 
of the olfactory system and the migration of GnRH neurons; in both, the olfactory axons 
and GnRH neurons left the olfactory placode but failed to reach the brain and instead 
accumulated over the cribriform plate (Schwanzel-Fukuda et al. 1989, Teixeira et al. 
2010). Therefore, it seems likely that anosmin-1 helps guide the olfactory axons and 
possibly also directly promotes GnRH neuron migration during embryonic development, 
especially around the nasal-forebrain junction (Hardelln et al. 1999, Cariboni et al. 
2004). Additionally, studies in chicken have provided some evidence for the 
involvement of anosmin-1 in the development of the cranial neural crest through the 
modulation of FGF8, BMP5, and WNT3a signaling (Endo et al. 2012). In adult rodents, 
new neurons arise in the subventricular zone and migrate to the olfactory bulb via the 
rostral migratory stream, and anosmin-1 overexpression increases the cell proliferation 
in the subventricular zone and the migratory activity of the neuroblasts, apparently 
through FGFR1 signaling (García-González et al. 2016).  
ANOS1 was the first gene whose mutations were identified to cause KS (Franco et al. 
1991, Legouis et al. 1991). ANOS1 mutations are identified in 5-10% of KS patients 
(Bianco & Kaiser 2009), they cause severe GnRH deficiency and seem to affect the sense 
of smell invariably (Hu & Bouloux 2011, Costa-Barbosa et al. 2013). Common 
additional findings in patients with ANOS1 mutations are bimanual synkinesia, unilateral 
renal agenesis, and cryptorchidism (Hu & Bouloux 2011, Costa-Barbosa et al. 2013). 
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FGFR1 (HGNC ID: 3688) and FGF8 (HGNC ID: 3686) 
FGF8 encodes fibroblast growth factor 8, and FGFR1 encodes fibroblast growth factor 
receptor 1. FGFs regulate morphogenesis during embryonic development through the 
regulation of cell proliferation, differentiation, and migration, and correct FGF/FGFR 
signaling is especially important for cranial, digital, and skeletal development 
(Eswarakumar et al. 2005). FGFs require HSPGs to bind to and activate the FGF 
receptors, and thus, HSPGs form a potential link between anosmin-1 and FGF signaling 
(González-Martínez et al. 2004). FGF8 signaling is crucial for correct midline facial 
integration, the formation of the nasal region, and the development of GnRH neurons 
(Kawauchi et al. 2005, Forni et al. 2013). Mice with hypomorphic Fgfr1 or Fgf8 
mutations either lack or have a significantly reduced amount of GnRH neurons, which 
seems to be the result of a defect in the early development of the neurons (Falardeau et 
al. 2008, Chung et al. 2008). The disrupted olfactory and GnRH neuron development 
may be secondary to defective craniofacial development in Fgf8 hypomorphic mice 
rather than due to a direct effect of FGF8 on GnRH neuron specification (Forni et al. 
2013). 
The first mutations in FGFR1 in KS patients were identified in 2003 (Dodé et al. 2003), 
and they are found in 10% of KS patients and in 6% of all CHH patients (Bianco & 
Kaiser 2009). In Finnish KS patients, FGFR1 mutations are the most frequently 
identified molecular genetic cause, especially in females (Laitinen et al. 2011). The first 
mutations in FGF8 were identified in 2008 (Falardeau et al. 2008) and are rarer than 
FGFR1 mutations; an FGF8 mutation is identified in less than 5% of KS patients and in 
less than 2% of all CHH patients (Bianco & Kaiser 2009). Both FGFR1 and FGF8 
mutations seem to cause autosomal dominantly inherited CHH. They can cause highly 
variable phenotypes even within the same family, ranging from apparently completely 
unaffected individuals, isolated anosmia, or delayed puberty to severe GnRH deficiency 
with variable non-reproductive anomalies (Dodé et al. 2003, Pitteloud et al. 2006a, 
Pitteloud et al. 2006b). Additionally, some patients with an FGFR1 mutation undergo 
reversal of CHH (Pitteloud et al. 2005, Raivio et al. 2007, Laitinen et al. 2012), and an 
FGF8 mutation has been found to underlie a case of adult-onset HH (Falardeau et al. 
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2008). Common associated anomalies in patients with FGFR1 or FGF8 mutations are a 
cleft lip or palate, dental agenesis, and ear and limb anomalies (Costa-Barbosa et al. 
2013). FGFR1 mutations have also been found to underlie various disorders of 
craniofacial and skeletal development, such as Pfeiffer syndrome, Hartsfield syndrome, 
and osteoglophonic dysplasia (Moosa & Wollnik 2016). 
PROK2 (HGNC ID: 18455) and PROKR2 (HGNC ID: 15836) 
PROK2 encodes prokineticin 2, and PROKR2 its receptor. PROK2 is a secreted protein 
that is involved in various biological processes such as circadian rhythms, pain 
perception, hematopoiesis, and immune response (Martin et al. 2011). The phenotype of 
homozygous Prok2- and Prokr2-knockout (KO) mice resembles Kallmann syndrome; 
they have hypoplasia of the olfactory bulbs and of the reproductive system, and a 
significantly reduced number of GnRH neurons in the hypothalamus (Ng et al. 2005, 
Matsumoto et al. 2006, Pitteloud et al. 2007b). Prok2-KO mice also have defective 
migration of neuroblasts through the rostral migratory stream to the olfactory bulbs (Ng 
et al. 2005). The most important mechanism by which PROK2/PROKR2 deficiency 
leads to GnRH deficiency seems to be the disrupted development of the olfactory system, 
although, as PROK2 and PROKR2 mutations have also been found in nHH patients, an 
additional direct effect on GnRH neurons cannot be ruled out (Martin et al. 2011). 
PROK2 and PROKR2 are also expressed in the gonads, so a direct effect on gonadal 
development/function may contribute to the phenotype (Matsumoto et al. 2006, Martin 
et al. 2011). Heterozygous mice are apparently unaffected, indicating that at least in 
mice, one functional Prok2/Prokr2 allele is sufficient for the normal development of the 
olfactory system and GnRH neurons (Ng et al. 2005, Matsumoto et al. 2006, Pitteloud 
et al. 2007b). 
PROK2 and PROKR2 mutations were first reported in KS patients in 2006 (Dodé et al. 
2006), and later also in nHH patients (Pitteloud et al. 2007b, Cole et al. 2008). Mutations 
in PROK2 and PROKR2 account for 5-10% of KS cases and 3-6% of all CHH cases 
(Bianco & Kaiser 2009). The mode of inheritance of PROK2 and PROKR2 mutations 
seems to be autosomal recessive, although heterozygous mutations have also been 
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reported in CHH patients (Dodé et al. 2006, Pitteloud et al. 2007b, Abreu et al. 2008, 
Tommiska et al. 2013a). Of note, PROKR2 mutations reported in nHH patients seem to 
be invariably heterozygous (Cole et al. 2008, Abreu et al. 2008, Martin et al. 2011), 
whereas one homozygous PROK2 mutation has been reported also in an nHH patient 
(Pitteloud et al. 2007b), which is in keeping with the fact that Prok2-KO mice seem to 
have a milder OB phenotype than Prokr2-KO mice (Matsumoto et al. 2006). No 
additional anomalies have been found to be significantly enriched in KS patients with 
PROK2 or PROKR2 mutations (Martin et al. 2011, Costa-Barbosa et al. 2013). 
Interestingly, no PROK2 or PROKR2 mutations have thus far been identified in Finnish 
CHH patients (Laitinen et al. 2011), but certain PROKR2 mutations are enriched in the 
Maghrebian population compared to Europeans, suggesting that the population may 
have undergone a bottleneck or a founder event, or that there are different selection 
pressures affecting PROKR2 allele frequencies in the Maghrebian population than in the 
European population (Sarfati et al. 2013).  
CHD7 (HGNC ID: 20626) 
CHD7 encodes the chromodomain helicase DNA-binding protein 7, which participates 
in gene expression regulation through chromatin remodeling (Basson & van 
Ravenswaaij-Arts 2015). CHD7 is expressed in the developing olfactory epithelium and 
olfactory bulbs, the hypothalamus, and several other neural and non-neural tissues 
during development in mice and humans (Layman et al. 2009). Chd7-deficient mice have 
olfactory defects, small olfactory bulbs, and a reduced number of olfactory sensory 
neurons (Layman et al. 2009), as well as a 30-35% reduction in the number of GnRH 
neurons in embryos and adult mice, and as a result, reproductive dysfunction (Layman 
et al. 2011). The reduced number of GnRH neurons may in part be explained by the 
finding that CHD7 is required for the formation of multipotent migratory neural crest 
cells (Bajpai et al. 2010). In adult mice, CHD7 is required for neurogenesis in the 
subventricular zone and the subgranular zone (Feng et al. 2013), as well as for neuronal 
regeneration in the olfactory epithelium (Layman et al. 2009).  
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Mutations in CHD7 were originally implicated in CHARGE syndrome (coloboma of the 
eye, heart defects, atresia of the choanae, severe retardation of growth/development, 
genital abnormalities and ear abnormalities), and the majority of patients with typical 
CHARGE syndrome are found to have a CHD7 mutation (Janssen et al. 2012). Some 
CHARGE patients also have hypogonadotropic hypogonadism and anosmia, which led 
Kim et al. (2008) to search for CHD7 mutations in patients with CHH and KS. Mutations 
were found in 6% of the patients, both in KS and CHH patients, which led the authors 
to conclude that CHH caused by CHD7 mutations is a milder allelic form of CHARGE 
syndrome (Kim et al. 2008). Jongmans et al. (2009) found CHD7 mutations in three out 
of 56 patients initially diagnosed with CHH. All three patients had anosmia and some 
phenotypic features of CHARGE syndrome, and two of them were later diagnosed as 
having CHARGE. The authors concluded that screening of CHD7 is useful especially in 
those CHH patients who have hearing impairment or other ear anomalies (Jongmans et 
al. 2009).  
SOX10 (HGNC ID: 11190) 
SOX10 (SRY (Sex Determining Region Y)-Box 10) encodes a transcription factor that 
is crucial for the differentiation of olfactory ensheathing cells, and thus for axonal 
targeting of olfactory axons and for the migration of GnRH neurons (Barraud et al. 2013, 
Pingault et al. 2013). SOX10 mutations have been traditionally associated with 
Waardenburg syndrome, which has some phenotypic overlap with Kallmann syndrome 
(Pingault et al. 1998, Bondurand et al. 2007). In fact, in 2013, mutations in SOX10 were 
also identified to underlie KS with hearing loss (Pingault et al. 2013), and they seem to 
contribute to a significant number of these cases (Pingault et al. 2013, Vaaralahti et al. 
2014). 
2.7.4 Genetic defects underlying normosmic CHH 
GNRH1 (HGNC ID: 4419) and GHRNR (HGNC ID: 4421) 
GNRH1 encodes the 92-amino acid preprohormone that is cleaved into the biologically 
active GnRH decapeptide, and GNRHR encodes the GnRH receptor. Homozygous or 
compound heterozygous mutations in these genes cause normosmic HH. The first 
53 
 
 
GNRHR mutations were reported in 1997 (De Roux et al. 1997), and 3.5-16% of sporadic 
nHH cases and up to 40% of familial cases are explained by GNRHR mutations (Bianco 
& Kaiser 2009). Some patients especially with milder GNRHR mutations undergo 
reversal of the phenotype (Raivio et al. 2007, Laitinen et al. 2012b). GNRH1 mutations 
are rare with only a few reported cases to date (Bouligand et al. 2009, Chan et al. 2009, 
Mengen et al. 2015).  
KISS1 and KISS1R 
KISS1 encodes a 145 amino acid protein that is cleaved into the 54, 14, 13 and 10 amino 
acid kisspeptins found in human (Kotani et al. 2001). The only KISS1 mutations causing 
nHH to date were reported in 2012 (Topaloglu et al. 2012). KISS1R, also known as 
GPR54, encodes the kisspeptin receptor, and the first mutations in this gene were 
identified in 2003 (Seminara et al. 2003, De Roux et al. 2003). KISS1 and KISS1R 
mutations are recessive, and KISS1R mutations are found to underlie nHH in about 5% 
of cases (Bianco & Kaiser 2009). 
TAC3 (HGNC ID: 11521) and TACR3 (HGNC ID: 11528) 
TAC3 and TACR3 encode neurokinin B and the neurokinin B receptor, respectively. The 
first mutations in TAC3 and TACR3 were reported in 2009 in four consanguineous 
families, where homozygous mutations in either gene were identified to underlie the 
phenotype (Topaloglu et al. 2009). The normal phenotype of heterozygous TAC3 and 
TACR3 mutation carriers points to recessive inheritance of the mutations (Guran et al. 
2009, Young et al. 2010, Francou et al. 2011), although mutations in these genes have 
been found in CHH patients also in the heterozygous state (Gianetti et al. 2010). 
2.7.5 Other genes implicated in CHH 
NSMF (HGNC ID: 29843, previously known as NELF; nasal embryonic LHRH factor) 
encodes NMDA receptor synaptonuclear signaling and neuronal migration factor. A 
heterozygous possibly pathogenic NSMF variant was first reported in an nHH patient in 
2004 (Miura et al. 2004). Since then, only a few NSMF variants have been reported, most 
of them heterozygous and present in combination with a variant in another CHH gene, 
suggesting NSMF variants may contribute to di/oligogenic inheritance of CHH but 
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heterozygous variants alone are probably not sufficient to cause CHH (Pitteloud et al. 
2007a, Xu et al. 2011). Female Nsmf-knockout mice have been reported to have reduced 
fertility and number of GnRH neurons in the hypothalamus (Quaynor et al. 2015). 
However, the biological role of NSMF is still under debate, as another report described 
Nsmf-KO mice with hippocampal dysplasia and no KS-associated features (Spilker et al. 
2016). 
WDR11 (HGNC ID: 13831) encodes WD repeat-containing protein 11, which is a 
possible interaction partner of the homeobox protein EMX1 that is involved in olfactory 
neuron development (Kim et al. 2010). WDR11 was identified as a CHH gene based on 
a balanced translocation on 10q26, located near WDR11, in a KS patient, and the 
subsequent screening of WDR11 in 201 CHH patients, revealing heterozygous, probably 
pathogenic variants in six patients (Kim et al. 2010). WDR11 variants were found both 
in KS and nHH patients. Few reports on WDR11 mutations in CHH patients exist, and 
WDR11 mutations have so far not been identified in Finnish KS patients (Laitinen et al. 
2011). 
FEZF1 (HGNC ID: 22788) encodes a zinc-finger protein that acts as a transcriptional 
repressor and is expressed in the olfactory epithelium, the amygdala, and the 
hypothalamus during embryonic development (Watanabe et al. 2009, Damla Kotan et 
al. 2014). In mice, Fezf1 seems to be required for the olfactory axons to be able to cross 
the central nervous system basal lamina, and deficiency of Fezf1 leads to the inability of 
olfactory axons to reach the olfactory bulb and to the disrupted migration of GnRH 
neurons (Watanabe et al. 2009). Consistently, homozygous recessive FEZF1 mutations 
have been identified in two consaguineous families, in which the affected individuals 
had severe HH and anosmia without any additional anomalies, indicating the importance 
of FEZF1 function during the development of the olfactory system also in human (Damla 
Kotan et al. 2014). In one of the families, another homozygous mutation in CCDC141 
was also identified, suggesting an additional genetic defect underlying the phenotype 
(Damla Kotan et al. 2014, Hutchins et al. 2016). CCDC141 encodes a coiled-coil 
domain-containing protein that is expressed in GnRH neurons and olfactory fibers 
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during the migration of GnRH neurons in mice. The knockdown of Ccdc141 in mouse 
nasal explants reduces the migration of GnRH neurons without affecting olfactory axons 
or GnRH neuron adhesion, suggesting a cell motility defect as the cause of the reduced 
migration and possible contribution of CCDC141 mutations to the CHH phenotype 
(Hutchins et al. 2016). 
Heparan sulfates (HS) are extracellular glycosaminoglycans that are important for the 
development of the nervous system (Inatani et al. 2003). 6-O-sulfated heparin sulfates 
seem to be especially important for the function of anosmin 1 in C. elegans, and also for 
the function of FGFR1 and FGF8 (Eak & Salmivirta 2002, Bülow et al. 2002, Tornberg 
et al. 2011). HS6ST1, encoding HS 6-O-sulfotransferase 1, was therefore screened in 338 
individuals with GnRH deficiency, of which 2% –both KS and nHH patients– were 
found to have either homozygous or heterozygous loss-of-function mutations in the 
gene, and some mutations were found in several individuals with widely varying 
phenotypes (Tornberg et al. 2011). The varying phenotypes and the presence of FGFR1 
and NSMF mutations in two families led the authors to suggest that HS6ST1 mutations 
may not alone be sufficient to cause full-blown GnRH deficiency (Tornberg et al. 2011). 
AXL encodes a member of the Tyro3-Axl-Mer receptor tyrosine kinase subfamily that 
transduces signals from the outside of the cell into the cytoplasm by binding GAS6 
(Hafizi & Dahlbäck 2006). Axl/Tyro3 double-knockout mice have a reduced number of 
GnRH neurons, delayed first estrus, and abnormal estrus cyclicity (Pierce et al. 2008), 
whereas Axl-knockout mice have a delayed first estrus and prolonged interval between 
vaginal opening and first estrus. This led Salian-Mehta et al. (Salian-Mehta et al. 2014) 
to screen 104 subjects with CHH for mutations in AXL. Four heterozygous variants were 
found, both in individuals with nHH and KS, and some were also reported in databases 
of genetic variation (Salian-Mehta et al. 2014). Although two of the variants showed 
partial loss of function in functional assays, none of them is most likely sufficient to 
cause the phenotype alone (Salian-Mehta et al. 2014). 
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FGF8 synexpression group 
FGF17 (HGNC ID: 3673), IL17RD (HGNC ID: 17616), DUSP6 (HGNC ID: 3072), 
SPRY4 (HGNC ID: 15533), and FLRT3 (HGNC ID: 3762) are all members of the so-
called ‘FGF8 synexpression group’, i.e. a group of genes whose expression pattern 
during development is similar to FGF8, and which are also able to modulate FGF8 
signaling through FGFR1 (Miraoui et al. 2013). Variants in these genes were recently 
identified in CHH patients, and FGF17 and IL17RD were deemed as the best CHH 
candidate genes based on their interactions with previously identified CHH genes. 
Mutations especially in the FGF8-signaling inhibitor IL17RD seem to be enriched in KS 
patients with hearing loss (Miraoui et al. 2013). 19% of the patients had variants in more 
than one gene of the FGF8 synexpression group or other known CHH genes, suggesting 
oligogenic inheritance; additionally, control subjects were found to carry some of the 
variants found in CHH patients, but a significantly higher proportion of the CHH patients 
compared to the controls carried two or more variants (Miraoui et al. 2013). 
CHH as part of other syndromes 
PCSK1 (HGNC ID: 8743) encodes proprotein convertase-1 that processes precursor 
proteins, such as prohormones, into smaller, bioactive products. Recessive mutations in 
PCSK1 cause the deficiency of several neuroendocrine hormones and insulin, leading to 
severe obesity, HH, hypocortisolism, elevated pro-opiomelanocortin (POMC) levels, 
and abnormal glucose homeostasis coupled with low levels of insulin and elevated levels 
of proinsulin as a result of impaired proprotein processing (Jackson et al. 1997). 
NR0B1, previously known as DAX1, is located on the X chromosome and encodes an 
orphan nuclear receptor that acts as a transcriptional regulator. Mutations in NR0B1 
cause X-linked adrenal hypoplasia congenita with hypogonadotropic hypogonadism 
(Muscatelli et al. 1994). Although the exact function of NR0B1 is still unclear, it seems 
to have a role in the development of the testes and the adrenal glands. NR0B1 mutations 
seem to cause a combined hypothalamic and pituitary defect leading to impaired 
gonadotropin secretion from the pituitary (Suntharalingham et al. 2015). Interestingly, 
some NR0B1 mutations result in early puberty, and one frameshift mutation in NR0B1 
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has also been identified in a boy with central precocious puberty and no signs of adrenal 
insufficiency (Shima et al. 2016). 
A homozygous recessive mutation in DMXL2 (HGNC ID: 2938), encoding 
rabconnectin-3?, was identified to underlie a new syndromic form of CHH in three 
brothers of a consanguineous family (Tata et al. 2014). The brothers had gonadotropin 
deficiency, central hypothyroidism, peripheral neuropathy, mental retardation, and 
diabetes (Tata et al. 2014). Rabconnectin-3? is a putative scaffold protein for the 
regulators of Rab3a, Rab3-GAP and Rab3-GEP, and it is expressed in exocytotic 
vesicles in GnRH neuron axonal extremities and in gonadotropes in the pituitary (Tata 
et al. 2014). Rabconnectin-3? is involved in regulated insulin secretion and most likely 
also in neurosecretion, and conditional Dmxl2-KO mice have a reduced number of 
GnRH neurons in the hypothalamus, possibly due to a mechanism where the defective 
neurosecretion leads to the loss of GnRH neurons in the hypothalamus (Tata et al. 2014). 
HESX1 (homeobox gene expressed in embryonic stem cells 1) is expressed in Rathke’s 
pouch during early development of the anterior pituitary, and it is important for the 
development of the pituitary, hypothalamus, optic nerve, and the forebrain (Dattani et 
al. 1998). HESX1 mutations have been identified in individuals with SOD, isolated 
growth hormone deficiency, and combined pituitary hormone deficiency, and more 
recently, also in some individuals with KS and no other associated anomalies (Newbern 
et al. 2013). Notably, all the KS patients had heterozygous mutations; HESX1 mutations 
have been identified both in homozygous and heterozygous states, and homozygous 
mutations seem to lead to a more severe phenotype such as SOD or panhypopituitarism 
(Newbern et al. 2013). 
Recessive mutations in PNPLA6 are implicated in the Gordon Holmes and Boucher-
Neuhäuser syndromes, which are characterized by ataxia, nHH, and either brisk reflexes 
(in Gordon Holmes syndrome) or chorioretinal dystrophy (in Boucher-Neuhäuser 
syndrome) (Synofzik et al. 2014). PNPLA6 encodes neuropathy target esterase, which 
de-esterifies phosphatidylcholine into fatty acids and glycerophosphocholine, which is 
required for the biosynthesis of acetylcholine. PNPLA6 mutations seem to disrupt the 
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ability of the pituitary gland to secrete gonadotropins in response to GnRH stimulus, 
although a contributing hypothalamic effect may also be present (Topaloglu et al. 2014). 
Digenic homozygous mutations in RNF216 and OTUD4 have also been identified in a 
consanguineous family with nHH, ataxia, and dementia (Margolin et al. 2013). 
Compound heterozygous and heterozygous RNF216 mutations were subsequently also 
identified in unrelated individuals with a similar phenotype, suggesting a potential di-or 
oligogenic inheritance (Margolin et al. 2013). RNF216 encodes a ubiquitin E3 ligase, 
and OTUD4 encodes a deubiquitinase, which, when knocked down simultaneously in 
zebrafish, exhibit a more severe phenotype than when either one is knocked down 
individually, suggesting an epistatic relationship between the two genes (Margolin et al. 
2013). This phenotype includes cerebellar hypoplasia, microphthalmia, and small optic 
tecta, indicating that loss-of-function mutations in the two genes are involved in 
neurodegeneration. The patients seemed to have defects at both the hypothalamic and 
pituitary levels, but the exact mechanism behind the reproductive phenotype remains 
unknown (Margolin et al. 2013). 
Recent advancements in the molecular genetics of CHH 
Heterozygous rare variants in IGSF10 were recently identified in several individuals 
with self-limited delayed puberty, CHH, or functional hypogonadism (Howard et al. 
2016). The function of IGSF10 is unknown, but it is expressed in the nasal mesenchyme 
of mice and human embryos at the time of GnRH neuron migration. Its knockdown 
reduces the migration of immature GnRH neurons in vitro as well as the migration and 
neurite outgrowth of GnRH3 neurons in zebrafish (Howard et al. 2016). The authors 
hypothesized that the pathogenic variants may lead to reduced GnRH neuron numbers 
in the hypothalamus or an impaired GnRH neuronal network, which may predispose the 
individuals carrying them to delayed puberty (Howard et al. 2016). It may be that other 
predisposing factors, such as mutations in other CHH genes, are needed for the 
phenotype to manifest, as most of the rare variants identified in delayed puberty/CHH 
patients are also reported in genetic variation databases (Howard et al. 2016).  
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Recessive mutations in POLR3B, encoding a subunit of RNA polymerase III, are known 
to cause 4H leucodystrophy, a syndrome consisting of ataxia, hypogonadotropic 
hypogonadism, and hypodontia (Tétreault et al. 2011). Recently, however, potentially 
pathogenic mutations in this gene were also found in individuals with CHH but without 
any signs of neurodegeneration or dental anomalies, expanding the phenotypic range 
caused by POLR3B mutations (Richards et al. 2016). One of these patients also showed 
resistance to GnRH treatment, suggesting a pituitary rather than a hypothalamic defect 
(Richards et al. 2016). 
A targeted next-generation sequencing approach of 261 genes known or suggested to be 
involved in CHH pathogenesis or in the development or function of GnRH neurons, the 
hypothalamus, the pituitary, or the olfactory system, revealed promising variants in 18 
novel candidate genes in 48 CHH patients (Quaynor et al. 2016). The authors suggested 
CCKBR, which encodes the cholecystokinin B receptor, to be one of the most promising 
candidate genes based on the cosegregation of a CCKBR variant with the phenotype in 
a large family (Quaynor et al. 2016). While these results are promising, extensive 
functional studies and larger patient cohorts are needed before anything conclusive can 
be said about the pathogenicity of the variants. 
Very recently, Kotan et al. (2016) reported inactivating mutations in the SRA1 gene, 
which functions both through a protein and a non-coding RNA product, in three families 
with nHH. The mutations appear to be recessive because the parents, who were 
heterozygous carriers, had normal pubertal development. In one of the families, the 
patients had a heterozygous mutation in SRA1 in combination with another heterozygous 
mutation in PNPLA6, suggesting digenic inheritance (Kotan et al. 2016). The authors 
suggested that SRA1 may regulate the expression of SF-1 target genes –including 
GNRHR and the gonadotropins—in the pituitary together with DAX1, thus in part 
regulating gonadotropin release from the pituitary (Kotan et al. 2016). 
2.7.6 Semaphorins 
The semaphorin family is a group of developmental guidance molecules, all 27 members 
containing a conserved sema domain responsible for the specificity of receptor binding 
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(Tamagnone & Comoglio 2000). The semaphorin family is divided into eight classes, of 
which classes 3-7 are found in vertebrates; class 3 semaphorins are secreted molecules, 
class 4-6 semaphorins have a transmembrane domain, and the one member of class 7 is 
glycosylphosphatidylinositol (GPI)-anchored to the cell membrane (Pasterkamp 2012). 
Semaphorins were first identified as having repulsive, growth-cone collapsing properties 
towards growing axons, but it is now known that they have diverse functions in the 
development of the nervous system, in vascular patterning, in the formation of different 
tissues, and in the immune system (Mann et al. 2007). Semaphorins bind to receptors 
located in the growth cones of growing axons, which induces changes in the cytoskeleton 
and cell adhesion to guide the axon to the appropriate target. They regulate, among other 
things, the targeting and branching of axons, axon bundling, the migration of neurons, 
apoptosis, the targeting and branching of dendrites, axonal pruning, and synaptic 
signaling (Mann et al. 2007). Semaphorins signal in neurons predominantly through 
receptor complexes containing plexins, nine of which have been identified in vertebrates 
(PLXNA1-4, PLXNB1-3, PLXNC1, and PLXND1) (Pasterkamp 2012). In addition, 
SEMA3 family members require neuropilins (either NRP1 or NRP2) in order to bind to 
the receptor complex (Pasterkamp 2012). Plexins are large transmembrane proteins that 
all have an extracellular sema domain and a conserved intracellular domain which can 
be phosphorylated and acts as an R-Ras guanosine triphosphatase –activating protein 
(Perälä et al. 2012). Several signaling molecules bind to the intracellular domains of 
plexins, thus allowing the activation of multiple intracellular signaling pathways in 
response to semaphorin binding (Franco & Tamagnone 2008). In addition, some 
membrane-spanning semaphorins are able to function as receptors for plexins and other 
semaphorins, thus allowing for even more diversity in semaphorin/plexin signaling 
(Pasterkamp 2012). 
SEMA3A (HGNC ID: 10723) 
SEMA3A is one of the most studied members of the semaphorin family, and it is the 
first identified member of the secreted semaphorin class (Sharma et al. 2012). SEMA3A 
signals mainly through receptors containing neuropilin 1 (NRP1), but in some cells it 
can also signal through NRP2-containing receptors (Cariboni et al. 2011). SEMA3A is 
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also able to signal through receptors containing any of the plexin A family members, 
plexin B1 or plexin D1, so SEMA3A signaling is not dependent on any one single plexin 
family member (Sharma et al. 2012). The role of SEMA3A in development has been 
studied extensively both in vitro and in mouse models, and it has been shown that 
SEMA3A can, among other things, regulate the formation of dendrites and the migration 
of neurons, induce neuronal apoptosis, promote the formation of axon bundles in the 
peripheral nervous system, and prevent the premature growth of axons during 
development as well as guide the migration of neural crest cells (Taniguchi et al. 1997, 
Huber et al. 2005, Mann et al. 2007, Osborne et al. 2005, Schwarz et al. 2009). Despite 
the diverse roles of SEMA3A during development, most Sema3A-KO mice do not seem 
to have as extensive developmental defects as might be expected, which may be due to 
the redundant roles of different guidance molecules during neuronal development 
(Taniguchi et al. 1997, Catalano et al. 1998). Behar et al. (1996), however, reported 
severe developmental defects in Sema3A-KO mice including skeletal, heart, and central 
nervous system defects leading to early postnatal death. These differences probably 
reflect the different genetic backgrounds of different laboratory mouse strains, which 
makes the interpretation of the results quite challenging (Taniguchi et al. 1997). 
Interestingly, the most severe axonal defects of the central nervous system in other 
Sema3A-KO mouse strains seem to affect the axons of the olfactory system and indicate 
that SEMA3A is involved in organizing the axons of the olfactory sensory neurons that 
project to the olfactory bulbs, thus participating in the formation of the topographic map 
of the olfactory system (Schwarting et al. 2000, Imai et al. 2009). Mice lacking either 
SEMA3A or both NRP1 and NRP2 also have a phenotype resembling Kallmann 
syndrome caused by ANOS1 mutations; their vomeronasal axons accumulate above the 
cribriform plate together with GnRH neurons and the mice have smaller testes, making 
SEMA3A a strong KS candidate gene (Cariboni et al. 2011). 
Mutations in SEMA3A have also been found in Kallmann syndrome patients: Young et 
al. (2012) reported a family, in which a heterozygous 213-kb deletion in SEMA3A, 
deleting the last 11 exons of the gene, was present in patients with KS with no other 
associated anomalies. KS seemed to be transmitted with an autosomal dominant mode 
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of inheritance with reduced penetrance in the family, as one family member had only 
isolated hyposmia and normal fertility (Young et al. 2012). Hanchate et al. (2012) 
screened 386 KS patients for SEMA3A mutations and reported a frameshift mutation and 
seven missense mutations, all in the heterozygous state, in 6% of the studied patients. 
All changes, excluding the frameshift mutations, had been previously reported in 
databases, and some of the variants were also present in healthy controls. Additionally, 
five patients had a mutation in another gene known to be involved in CHH (ANOS1, 
FGFR1, PROKR2, or PROK2), leading the authors to conclude that the identified 
SEMA3A mutations are most likely not sufficient to cause the phenotype on their own 
but most likely contribute to the pathogenesis of KS together with mutations in other 
genes (Hanchate et al. 2012). 
SEMA7A (HGNC ID: 10741) 
Semaphorin 7A was originally detected in the immune system and is the closest relative 
of viral semaphorins (Lange et al. 1998). SEMA7A can be present both as a GPI-
anchored membrane protein and as a soluble protein, and it signals through both plexin 
C1 and β1-integrins (Pasterkamp et al. 2003, Pasterkamp 2012). SEMA7A stimulates 
the production of cytokines in monocytes and monocyte movement as well as their 
differentiation into dendritic cells (Holmes et al. 2002), and Sema7A-knockout mice 
have a deficient T-cell-mediated inflammatory response (Suzuki et al. 2007). SEMA7A 
also has a potential role in the differentiation of osteoblasts and osteoclasts (Delorme et 
al. 2005), and some SEMA7A polymorphisms are associated with bone density (Koh et 
al. 2006). SEMA7A also carries the John Milton Hagen blood group antigens (Seltsam 
et al. 2007).  
Among its many functions, SEMA7A is also involved in the development of the nervous 
system. During development, SEMA7A is expressed in the neural crest in chick (Bao & 
Jin 2006), and in the median eminence and other parts of the hypothalamus, Rathke’s 
pouch and the later developing adenohypophysis, olfactory epithelium, olfactory bulbs, 
and other parts of the developing nervous system in rat (Pasterkamp et al. 2007). Both 
the GPI-anchored and the soluble form of SEMA7A promote axon growth, and 
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SEMA7A signaling through β1-integrins promotes axon outgrowth from the olfactory 
bulbs to the olfactory cortex (Pasterkamp et al. 2003).  
SEMA7A is expressed along the axons of olfactory and vomeronasal nerves during 
mouse development and promotes the migration of GnRH neurons through β1-integrin-
dependent signaling (Messina et al. 2011). Sema7A-KO mice have approximately a 30% 
reduction in the number of GnRH neurons in their brains, the number of GnRH fibers in 
the ME is reduced, and their fertility is also significantly reduced compared to wild-type 
littermates (Messina et al. 2011). The olfactory system, however, develops normally in 
these mice, suggesting SEMA7A promotes the migration of GnRH neurons directly but 
is not crucial for the correct growth and targeting of the nerves of the olfactory system 
(Messina et al. 2011). Targeted disruption of Itgb1 in mouse GnRH neurons leads to a 
30% reduction of GnRH-neuron cell bodies in the adult mouse brain, and innervation of 
the ME by GnRH fibers is reduced by over 70% in females and 33% in males: 
accordingly, female GnRH-Itgb1-KO mice also have significantly reduced fertility 
compared to wild-type mice (Parkash et al. 2012). Based on the phenotype of Sema7A-
KO mice, SEMA7A is a promising candidate gene for normosmic HH, but the role of 
SEMA7A mutations in the pathogenesis of CHH is still unclear. 
SEMA3E (HGNC ID: 10727) 
Recently, a heterozygous missense mutation in another secreted semaphorin, SEMA3E, 
previously identified to be involved in vascular patterning, axonal guidance, and synapse 
formation, was identified in two brothers with KS (Cariboni et al. 2015). Unexpectedly, 
SEMA3E seems to protect maturing GnRH neurons in the brain rather than promote 
their migration. In mice where either Sema3E or its receptor, PlxnD1 had been knocket 
out, there was increased apoptosis of GnRH neurons in the developing brain, and 
innervations to the ME were reduced (Cariboni et al. 2015). The brothers also had a 
heterozygous mutation in CHD7, and it is unclear to what extent the different mutations 
are responsible for the phenotype (Cariboni et al. 2015). A heterozygous de novo 
mutation in SEMA3E has also been identified in a patient with CHARGE syndrome 
(Lalani et al. 2004). As no other reports on SEMA3E mutations in CHARGE patients 
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exist, the role of SEMA3E mutations in the pathogenesis of CHARGE syndrome remains 
unresolved (Sanlaville & Verloes 2007). 
Semaphorin signaling in the postnatal brain 
Recent studies have provided evidence that, in addition to guiding the migration of 
GnRH neurons during embryonic development, semaphorin signaling may also be 
involved in the morphological changes occurring throughout the estrous cycle in 
response to changing levels of estrogen and progesterone in rodents (Giacobini et al. 
2014, Parkash et al. 2015). Recently, Parkash et al. (2015) showed that Semaphorin 7A 
functions also in the adult rodent brain to modulate the connections of GnRH neuron 
terminals to the ME. SEMA7A is secreted by tanycytes, the ependymal cells surrounding 
GnRH neuron nerve terminals, in response to circulating ovarian steroids, and the 
expression is highest on the day of the diestrus. GnRH neurons express PlexinC1, and 
when SEMA7A signals through this receptor, it causes the nerve terminals to retract. At 
the same time, mediated by SEMA7A signaling through ITGB1, tanycyte processes 
expand to further eliminate contact between GnRH neurons and the ME (Parkash et al. 
2015). This mechanism could provide one link between changes in the circulating sex 
steroids and changes in GnRH secretion from the hypothalamus. The physiological 
relevance of this mechanism is seen in female PlexinC1-KO mice, which lack normal 
estrous cyclicity and have reduced fertility as a result (Parkash et al. 2015). In contrast, 
SEMA3A, which is expressed by vascular endothelial cells in the ME, has an opposite 
effect on the GnRH nerve terminals, which also express the SEMA3A receptor NRP1 
(Giacobini et al. 2014). The 65 kDa isoform of SEMA3A reaches a peak in expression 
on the day of proestrus in the ME of female rats in response to circulating estradiol, and 
promotes the growth of the GnRH nerve terminals towards the vascular walls. The 
disruption of SEMA3A/NRP1 signaling in rats leads to abnormalities in the ovarian 
cycle, demonstrating the importance of SEMA3A as a regulator of GnRH neuron access 
to the ME during the different phases of the estrous cycle (Giacobini et al. 2014). 
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3. AIMS OF THE STUDY 
To identify genetic causes of disorders where the normal timing of pubertal development 
or normal development of sex is disrupted. Specifically, to investigate:  
1) the cause of complete androgen insensitivity syndrome in two patients without 
mutations in the coding region or conserved splice sites of the androgen receptor 
gene (I) 
2) if mutations in MKRN3 contribute to gonadotropin-dependent precocious 
puberty in Danish girls (II) 
3) the genetics of congenital hypogonadotropic hypogonadism in Denmark (III) 
4) whether mutations in the candidate CHH genes SEMA3A and SEMA7A are 
present in Finnish patients with congenital hypogonadotropic hypogonadism 
(IV) 
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4. SUBJECTS AND METHODS 
4.1 Subjects 
4.1.1 Subjects with CAIS 
The two subjects with CAIS were born to a non-consanguineous couple after normal 
pregnancy and birth. They are the first (A) and the third (B) child in the family; the 
second child is a 46,XX girl. The first child was tested for her karyotype after an 
operation to treat an inguinal hernia revealed a gonad in the hernia sac. Her karyotype 
was found to be 46,XY, and ultrasound and MRI revealed completely feminine external 
genitalia and abdominal gonads, which were confirmed to be functional testicular tissue 
based on serum testosterone and inhibin levels (2.5 nmol/l and inhibin-B 668 pg/ml, 
respectively, at 3 months 3 weeks age). The vagina was only 0.7 cm. MRI revealed no 
uterine structures. Her serum hormone levels at the age of 12.9 years were: LH 19 U/L, 
FSH 4.1 U/L, testosterone 29 nmol/L, estradiol 0.149 nmol/L, and inhibin B 426 ng/L, 
which verifies functional testicular tissue.  
Child B was karyotyped from the amniotic fluid and the result (46,XY) was confirmed 
after birth. Her phenotype was identical to that of the first child, with no uterine 
structures found in the MRI. At the age of 8.9 years, her serum hormone levels were: LH 
3.2 U/L, FSH 4.4 U/L, testosterone 1.1 nmol/L, estradiol <0.025 nmol/L, and inhibin B 
222 ng/L, which is consistent with the presence of functional testicular tissue and 
commencing puberty. 
4.1.2 Subjects with GDPP  
29 girls with GDPP were recruited from the outpatient clinic at the Department of 
Growth and Reproduction, Copenhagen University Hospital. Details of this study have 
been published previously (Sørensen et al. 2010b). In short, the girls were diagnosed 
with GDPP if their age at onset of breast development was <8 years, peak-LH level in 
response to rapid-acting GnRHa was >5 IU/l, and their brain MRI was normal. The girls 
had previously been screened for mutations in KISS1, KISS1R, LIN28A, and LIN28B, 
but no causative mutations had been found (Tommiska et al. 2011).  
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4.1.3 Danish subjects with KS or normosmic CHH 
All patients registered with an ICD10 code corresponding to CHH (DE23.0D) were 
identified through the register of the Department of Growth and Reproduction, 
Copenhagen University Hospital, and the diagnosis was validated by carefully 
evaluating the patient records. All clinical and biomedical data were reordered and 
results from dual-energy X-ray absorptiometry, brain MRI, and sense of smell (tested or 
self-reported) were included when available. DNA from 41 male patients with CHH was 
available through the biobank. 
4.1.4 Finnish subjects with KS or normosmic CHH 
50 patients were previously diagnosed as having CHH based on i) clinical signs and 
symptoms of hypogonadism (absent puberty, infertility, decreased libido), ii) low sex 
steroid levels in association with inappropriately low or normal gonadotropin levels, and 
subnormal/normal response to GnRH stimulation test, iii) otherwise normal anterior 
pituitary function, iv) normal radiological imaging of the hypothalamic and pituitary 
areas, and in case of KS, v) defective sense of smell detected by formal testing (UPSIT 
score <5th percentile of age (University of Pennsylvania Smell Identification Test, 
Sensonic, Haddon Heights, NJ, USA)) and/or absent or rudimentary olfactory bulbs in 
MRI. The patients were enrolled from all five university hospitals in Finland. All patients 
had previously been screened for mutations in the known CHH genes (FGFR1, FGF8, 
PROK2, PROKR2, CHD7, WDR11 (all patients), ANOS1 (KS patients only), GNRHR, 
GNRH1, KISS1R, KISS1, TAC3, and TACR3 (nHH patients only)). Of the 50 patients, 
20 had been found to have mutation(s) in ANOS1 (3 patients), FGFR1 (12 patients), 
GNRHR (4 patients), or CHD7 (1 patient). Thirty of the patients had not been found to 
have a conclusive mutation in any of the known CHH genes. Of the mutation-negative 
patients, 19 (18 men, 1 woman) had KS, 9 (7 men, 2 women) had nHH, and two men 
had adult-onset HH. 
4.1.5 Controls 
Controls were from the same geographical region as the subjects. The controls used in 
study III were 95 healthy prepubertal girls from the Copenhagen Puberty study 
(Aksglaede et al. 2009). Controls used in study IV were DNA samples from 200 healthy 
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anonymous blood donors obtained from the Finnish Red Cross blood service. 
Additionally, the presence and the frequency of the identified variants were checked 
from the dbSNP (https://www.ncbi.nlm.nih.gov/SNP/) (studies I and III), NHLBI 
Exome Sequencing Project (Exome Variant Server, http://evs.gs.washington.edu/EVS/) 
(studies II, III and IV), and 1000 Genomes (www.1000genomes.org; phase 3, all 
variants) (study I) databases. 
4.1.6 Ethical issues 
All participants and the guardians of participants less than 16 years old gave their written 
informed consent. Studies I and IV were approved by the Ethics Committee of the 
Helsinki University Central Hospital, study II was approved by the scientific ethics 
committee for Copenhagen and Frederiksberg (KF 01 282214 and KF 11 2006-2033) 
and the Danish Data Protection Agency, and study III was approved by the regional 
ethics committee (KF01328087) and the Danish Data Protection Agency (2006-41-
7251). All studies adhered to the approved guidelines. 
4.2 Sanger-sequencing  
The Sanger-sequencing method was used to screen the AR gene (RefSeq ID: 
NM_000044) in the two CAIS patients (study I); MKRN3 (NM_005664.3) in the Danish 
girls with GDPP (study II); ANOS1 (NM_000216.3), FGFR1 (NM_023110.2), FGF8 
(NM_033163.3), PROK2 (NM_001126128.1), PROKR2 (NM_144773.2), GNRHR 
(NM_000406.2), TAC3 (NM_013251.3), TACR3 (NM_001059.2), and KISS1R 
(NM_032551.4) in the Danish HH patients, as well as CHD7 (NM_017780.3) in the two 
patients with hearing loss (study III); and SEMA3A (NM_006080.2) and SEMA7A 
(NM_003612.4) in the Finnish patients with CHH (study IV).  
Genomic DNA samples had been previously obtained from all patients by extraction 
from peripheral blood leukocytes. Coding exons and exon-intron boundaries of the genes 
were PCR-amplified from the genomic DNA samples and purified with ExoSAP-IT 
(Amersham Biosciences, Piscataway, NJ, USA) or illustra ExoProStar 1-step (GE 
Healthcare Life Sciences, Chicago, IL, USA) treatment. The purified products were 
sequenced bi-directionally using the ABI BigDyeTerminator Cycle Sequencing Kit 
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(v3.1) and ABI Prism 3730xl DNA Analyzer automated sequencer (Applied Biosystems, 
Foster City, CA, USA). The sequences were aligned and read with the Sequencher 
software (v4.9 or v5.4.1) (Gene Codes Corporation, AnnArbor, MI, USA). 
4.3 Whole-genome resequencing 
Whole-genome resequencing of the two siblings with CAIS and of their healthy father 
was performed at the Beijing Genomics Institute (BGI, Shenzhen, China) by using 
Illumina’s HiSeq 2000 technology. 
4.4 Bioinformatic analysis of mutations 
The effects of the identified missense mutations were predicted with the web-based 
analysis tools PolyPhen2 (Adzhubei et al. 2013) (studies II, III, and IV), SIFT (Kumar 
et al. 2009) (study II), and Mutation Taster (Schwarz et al. 2014) (study II). The effects 
of identified splice-site mutations were predicted with the web-based analysis tool 
Human Splicing Finder v.2.4.1 or v.3.0 (Desmet et al. 2009) (studies I and III). All 
analyses were performed with the default settings. 
4.5 RNA extraction and cDNA synthesis 
TriPure Isolation Reagent (Roche) was used to extract total RNA from cultured cells 
according to the manufacturer’s recommendations, and RNA pellets were suspended in 
30 μl of sterile H2O. Complementary DNA (cDNA) synthesis was done with 
Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics) using 1 μg of RNA 
in a 20 μl volume, and the cDNA samples were further diluted into 200 μl with sterile 
H2O. 
4.6 AR cDNA sequencing  
The entire coding region of AR cDNA was PCR-amplified in overlapping fragments 
from the cDNA samples obtained from the patients’ genital skin fibroblasts, control 
fibroblasts, and LNCaP cells. The PCR products were visualized on a 1.5% agarose gel. 
The different-sized bands produced from the patient samples were extracted from the gel 
with QIAquick gel extraction kit (Qiagen, Hilden, Germany) and were sequenced as 
described above (section 4.2). 
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4.7 RT-qPCR analysis 
A 4 μl aliquot of cDNA was used in each qPCR reaction, which contained 0.4 μM each 
primer and 1 x LightCycler® 480 SYBR Green I Master (Roche) in a 10 μl reaction 
volume. The PCR program was as follows: denaturation at 95 ˚C for 10 min, 40 cycles 
of 95 ˚C, 20 sec; 58 ˚C, 20 sec and 72 ˚C, 20 sec, and final extension 72 ˚C for 5 min. 
The primers used are listed in table 3. Quantification of the normally spliced AR mRNA 
was performed with primers targeting specifically the normal variant with the reverse 
primer located at the junction of exons 6 and 7. The results were calculated for each gene 
of interest in relation to GAPDH expression. Further, the results of all samples were 
expressed in relation to control sample XX31B vehicle (0.1% ethanol) treatment (value 
set to 1) using the formula 2-(ΔΔCt), where ΔΔCt is ΔCt(sample)-ΔCt(XX31B vehicle), ΔCt is Ct(gene 
of interest)-Ct(GAPDH) and Ct is the cycle where the threshold value is crossed. 
 
Table 3. Sequences of the primers used in the RT-qPCR reactions 
Total AR mRNA Forward 5’- TTGGAGACTGCCAGGGAC-3’ 
 
Reverse 5’- TCAGGGGCGAAGTAGAGC-3’  
FKBP5 Forward 5’- AAAAGGCCAAGGAGCACAAC-3’ 
 
Reverse 5’-TTGAGGAGGGGCCGAGTTC-3’  
GAPDH Forward 5’-TGGGGAAGGTGAAGGTCGG -3’ 
 
Reverse 5’-TCTCAGCCTTGACGGTGCC-3’  
Normally spliced AR Forward 5’- CAGTGTGTCCGAATGAGGCA-3’  
 
Reverse 5’- CCCATCCACTGGAATAATGCTGA-3’  
 
4.8 Cell culture 
Patient fibroblasts (obtained from the labia majora) and human control fibroblasts were 
grown in Dulbecco's Modified Eagle Medium (Gibco, Life Technologies, 41965, 
Paisley, Scotland) supplemented with 1% (vol/vol) penicillin and streptomycin and 10% 
fetal calf serum (FCS; HyClone, Thermo Scientific SV30160-03, Gramlington, UK). 
LNCaP prostatic cancer cells were grown in RPMI (Gibco, Life Technologies, A10491, 
Grand Island, NY, USA) supplemented with 1% (vol/vol) penicillin and streptomycin 
and 10% FCS. For the experiments, the cells were split onto 6-well plates (250 000 
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cells/well) and allowed to grow for 24 h, after which the cells were incubated in steroid-
depleted medium (fibroblasts in Dulbecco's Modified Eagle Medium supplemented with 
2.5% stripped serum and LNCaP cells in RPMI supplemented with 10% stripped serum) 
for 6 h. Subsequently, vehicle (0.1% EtOH) was added to a half and 1 nM AR agonist 
methyltrienolone (R1881) (Perkin Elmer, NCP-005, Boston, MA, USA) to a half of the 
wells. Cells were collected for immunoprecipitation or RNA extraction 18 hours after 
the addition of vehicle or R1881. 
4.9 Immunoprecipitation and western blotting 
Cells were collected by using phosphate-buffered saline containing 10 mM N-
ethylmaleimide, and cells from three wells were pooled into one sample yielding 
approximately 2 million cells. The cells were resuspended in lysis buffer (50 mM Tris-
HCl, pH 8.0, 140 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1% (vol/vol) Triton 
X-100, 10% glycerol, 10 mM Na-phosphate, 50 mM NaF, 10 mM N-ethylmaleimide, 1x 
protease inhibitor cocktail (cOmplete Protease Inhibitor Cocktail tablets, Roche 
Diagnostics GmbH, Mannheim, Germany)) and incubated on ice for 20 min, after which 
they were sonicated for 10 sec, centrifuged at 13000 x g for 20 min at +4 ˚C, and the 
supernatants were transferred into new tubes. The supernatants were precleared in 
rotation at +4 ˚ C for 1h with magnetic beads that had been equilibrated in the lysis buffer 
containing 0.5% bovine serum albumin (BSA). A magnet was used to separate the beads 
from the supernatant from which an aliquot was taken to serve as an input sample. 
The immunoprecipitation was performed with Magna ChIP™ Protein A magnetic beads 
(Millipore, Temecula, CA, USA) by using a polyclonal antibody (rabbit α-AR 
(Karvonen et al. 1997)) raised against the full-length AR coupled to beads in lysis buffer 
which contained 0.5% BSA in rotation over night at +4 ˚C. The supernatants were 
immunoprecipitated with beads coupled to the antibody in rotation at +4 ˚C overnight, 
after which the beads were washed thrice with the lysis buffer. 1 x sodium dodecyl 
sulfate sample buffer containing 10 mM N-ethylmaleimide and 1 x protease inhibitor 
cocktail was used to elute the immunoprecipitated proteins from the beads, and the input 
and the immunoprecipitated samples (corresponding to 40% of each immunoprecipitate) 
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were run on sodium dodecyl sulfate polyacrylamide gel electrophoresis gels followed by 
transfer onto nitrocellulose membranes. A mouse monoclonal α-AR antibody 441 
targeting amino acids 299-315 of the N-terminal domain (sc-7305, Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) and a horseradish-peroxidase-conjucated 
anti-mouse secondary antibody (Life Technologies, Eugene, OR, USA) were used to 
detect AR on the membrane. To determine the loading of the input samples, a rabbit 
polyclonal α-GAPDH antibody (sc-25778; Santa Cruz Biotechnology Inc.) was used. 
4.10 Amplification of MKRN3 from a hypothalamic cDNA library 
Expression of MKRN3 in adult human hypothalamus was investigated by amplifying a 
598-bp-long fragment of the MKRN3 cDNA from a commercial human hypothalamic 
cDNA library (Clontech Alboratories Inc., Mountain View, CA, USA). The hypothalami 
of altogether 30 male and female Caucasians aged 15-68 years had been collected after 
sudden death to construct the cDNA library. Cyclophilin G served as a positive control 
gene for the PCR. Following amplification, the PCR products were visualized on a 2.0% 
agarose gel. 
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5. RESULTS 
5.1 Deep intronic AR mutation leading to CAIS 
5.1.1 Genomic sequencing and cDNA analysis of AR 
Sanger sequencing of the coding region and the exon-intron boundaries of AR revealed 
no rare potentially pathogenic variants. Both CAIS siblings had only one synonymous 
polymorphism (c.639G>A p.(Glu213=), rs6152, minor allele frequency 0.24 in the 1000 
Genomes (www.1000genomes.org; phase 3,  all variants) database) in the coding region 
of AR.  
The entire coding region of AR cDNA was PCR amplified and the products were 
visualized on a 1.5% agarose gel. Amplification with primers situated on exon 5 and the 
3’untranslated region (UTR) produced two abnormally long products from the patients’ 
cDNA samples, and a significantly reduced amount of the normal-sized product as 
compared to the control fibroblasts (Figure 6).  
 
Figure 6. PCR amplification of AR cDNA with primers situated on exon 5 and the 3’UTR 
from the cDNA samples of patient (T1, T2) and control (XX31B, XY31A) fibroblasts and 
LNCaP cells. 
 
Whole-genome sequencing of the two CAIS patients and their father yielded sequencing 
data with an average sequencing depth of ≥35.14 and ≥99.68% coverage for each sample. 
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The AR gene region (GRCh37 genomic position chrX:66,764,465-66,950,461) had an 
average sequencing depth of ≥19.04 and at least 99.4% bases had ≥4x coverage in each 
sample. The data revealed a point mutation, c.2450-118A>G (GRCh37 genomic location 
chrX:66,942,551), in intron 6 of AR, consistent with the observed abnormal splicing of 
the cDNA. The mutation was not reported in the dbSNP or the 1000 Genomes database, 
and it was confirmed by Sanger sequencing to be present as hemizygous in both CAIS 
patients, heterozygous in their mother, and absent in the father and the healthy sister 
(Figure 7). The whole-genome sequencing data revealed no other potentially pathogenic 
variants in the AR gene region. 
 
Figure 7. Sanger sequencing of the deep intronic mutation in intron 6 of AR. The mutated 
base (c.2450-118A>G) is marked with black. The mutation was hemizygous in both affected 
siblings with CAIS, heterozygous in their mother, and absent in the father and the healthy sister. 
 
5.1.2 In silico analysis with Human Splicing Finder 
According to the in silico analysis, the intronic mutation may create either a new acceptor 
splice site [+61.08% increase in the motif score from 47.4 (wild type), to 76.35 (mut) 
with the HSF prediction algorithm (consensus value (CV) threshold 65, variation 
threshold +/-10%)] or a new donor splice site [+15.34% increase of the score from 68.92 
(wild type) to 79.49 (mut) with the HSF prediction algorithm (CV threshold 65, variation 
threshold +/-10%), and +1053.95% increase from 0.76 (wild type) to 7.25 (mut) with 
75 
 
 
MaxEntScan algorithm (CV threshold 3, variation threshold +/-30%)]. In addition to a 
new splice site, HSF predicted that the mutation may also create a new exonic splicing 
enhancer (ESE) motif for the serine/arginine-rich splicing factor SRSF1 (SF2/ASF) 
[mutant motif value 75.19 with ESE Finder algorithm (threshold value 72.98)]. 
5.1.3 Sequencing of the AR cDNA 
Consistent with the in silico analysis, the sequencing of the abnormal products revealed 
the addition of either 85 bp of intronic sequence which comprised the mutated base and 
the 84 nucleotides upstream of the mutation, or 202 bp of intronic sequence comprising 
the aforementioned 85 nucleotides and all of the intronic sequence downstream of the 
mutation site leading up to exon 7 (Figure 8). Thus, the mutation led to the formation of 
two abnormally spliced mRNAs that contained either a new cryptic 85-bp exon between 
exons 6 and 7, or an abnormally long exon 7 containing 202 bp of the upstream intronic 
sequence. 
5.1.4 AR protein analysis and quantification of AR cDNA 
Both abnormal splice variants code for 12 additional amino acids (NRIQLSFPLRSP) 
followed by a premature termination codon (PTC) after amino acid 816. Both aberrant 
AR mRNA isoforms are predicted to undergo nonsense-mediated decay due to the 
presence of an intron downstream of the PTC (Isken & Maquat 2007). RT-qPCR analysis 
revealed that the patient fibroblasts expressed overall similar amounts of AR mRNA 
when compared to control fibroblasts (Figure 9a), but the amount of the normally 
spliced AR mRNA in patient fibroblasts was only approximately 10% of the expression 
levels in the XX31B control fibroblasts (T1: 9.0-10.9% expression, T2: 11.6-12.9% 
expression) (Figure 9b). Consistent with the qPCR result, AR protein was undetectable 
in the patient samples in the western blot performed after immunoprecipitation with a 
polyclonal anti-AR antibody, although it was detected in the control fibroblast samples 
(Figure 9c). The expression of both the AR mRNA and the AR protein were significantly 
higher in the LNCaP prostate cancer cell line in comparison to the sample and control 
fibroblasts. Androgen-receptor signaling was examined in patient and control cells by 
adding the AR agonist R1881 to the cells and quantitating the expression of the 
76 
 
 
androgen-inducible gene FKBP5, but the amount of AR was sufficient for any induction 
only in the LNCaP cells (Figure 10).  
 
Figure 8. The schematic representation of the two aberrant mRNAs (A), sequence 
chromatograms showing the borders of the normal and cryptic exons of the two aberrant 
splice variants (B), and the nucleotide sequences of exon6 and 7, intron 6 and the cryptic 
exons (C). A) In splice variant 1, there is a new 5’splice site (ss) motif where the U1 snRNP 
binds; in splice variant 2, there is a new exonic splicing enhancer (ESE) motif where the splicing 
factor SRSF1 binds. In both scenarios, the cryptic exonic sequences are marked with Ψ. B) 
Sequence chromatograms showing the borders of the normal exons and the cryptic sequences of 
splice variant 1 (top two chromatograms) and 2 (bottom two chromatograms).  C) The nucleotide 
sequences of the cryptic exons and the flanking exons and introns. The identified mutation is in 
bold. The cryptic exonic sequences are highlighted in yellow (and red/green) and correspond to 
the boxes marked with Ψ in panel A. The new splicing motifs created by the mutation are 
highlighted either in red (5’ splice (donor) site) or in green (ESE motif). 
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Figure 9. The quantification of the total AR mRNA (A), the normally-spliced AR mRNA 
(B), and the AR protein (C) expression. Control (XX31B, XY31A, XX54A) or patient (T1, T2) 
fibroblasts and LNCaP cells were seeded on 6-well plates and after 24h, the medium was changed 
to steroid-depleted medium for 6h. The cells were treated with 1nM R1881 (+) or vehicle (-) 
(0.1% EtOH) for 18h before RNA extraction (A, B) or immunoprecipitation (C). In A and B, the 
expression of total AR mRNA (A) or the normally spliced AR mRNA (B) was quantitated with 
RT-qPCR. GAPDH served as the reference gene. Expression in all samples was normalized to 
the expression in vehicle-treated XX31B cells. Normally spliced AR mRNA was quantitated from 
vehicle-treated samples. In C, AR was immunoprecipitated with a rabbit polyclonal α-AR 
antibody and detected in western blot with a mouse monoclonal α-AR antibody. GAPDH served 
as a reference to control for the loading of the input samples. 
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Figure 10. Quantification of the androgen-inducible FKBP5 gene mRNA expression in 
response to the AR agonist R1881. Control (XX31B, XY31A, XX54A) or patient (T1, T2) 
fibroblasts and LNCaP cells were seeded on 6-well plates. After 24h, the medium was changed 
to steroid-depleted medium for 6h, after which the cells were treated for 18h with 1nM R1881 
(+) or vehicle (-) (0.1% EtOH). Expression of FKBP5 was quantitated with RT-qPCR. GAPDH 
served as the reference gene, and the expression in all samples was normalized to the expression 
in vehicle-treated XX31B cells. Bars represent mean ± SD of 3-5 independent samples. 
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5.2 MKRN3 
5.2.1 Results of MKRN3 screening in Danish GDPP patients 
Screening of MKRN3 revealed one heterozygous missense mutation, c.1034G>A 
p.(Arg345His), in one Danish girl with GDPP, who was born from non-consanguineous 
Caucasian parents. The girl had experienced periodic breast enlargement starting at 6 
years of age and rapid breast and pubic hair development starting at 7 years. At 7.5 years, 
she had breast stage 4 and pubic hair stage 3, accelerated linear growth (height SDS 
+2.0) and advanced bone age (10 years Greulich Pyle). She had pubertal LH response 
(from 1.28 to 32.2 IU/l) to a GnRH test (0.1 mg Relefact), basal estradiol 68 pmol/l, 
inhibin B 124 pg/ml, and IGF-1 469 ng/ml (2.82 SDS). MRI of the brain was normal. 
The girl was treated with GnRH analogue for 2 years, after which it was stopped, and 
subsequently, her puberty resumed and she had menarche at 11.5 years of age. She had 
final height of 164.2 cm (target height was 169.2 cm). 
The same mutation was also identified in the girl’s brother, who had a very early voice 
break at 10.5 years, indicating early pubertal development. His puberty, however, was 
not formally assessed. He also had cystic fibrosis and was therefore seen at regular visits. 
The siblings had inherited the mutation from their father, since the mother did not have 
it. The father’s puberty was described as average, and the mother had normal timing of 
menarche at 11 years old. 
The mutation has been reported with a frequency of 1/8,600 chromosomes in the 
European American population in the EVS database. The mutation is situated in the 
C3HC4 RING domain of MKRN3, and is predicted to be deleterious by PolyPhen-2 
(“probably damaging”, score 0.01), Mutation Taster (“disease causing”, probability 
0.999999998), and SIFT (“affects protein function”, score 0.01). 
No other mutations in MKRN3 were identified in the 29 Danish girls with GDPP. 
5.2.2 Expression of MKRN3 in an adult human hypothalamic cDNA library 
The PCR amplification of the MKRN3 cDNA, visualized by agarose gel electrophoresis, 
revealed strong expression in the human hypothalamic cDNA library (Figure 11). 
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Figure 11. PCR amplification of MKRN3 cDNA from the human hypothalamic cDNA 
library. MKRN3 expression in adult human hypothalamus was investigated by PCR-
amplification of a 598-bp fragment of the MKRN3 cDNA from a commercial hypothalamic 
cDNA library. Cyclophilin G was used as a positive control for the PCR. The PCR products were 
visualized on a 2.0% agarose gel. NT: no template (negative control). 
 
5.3 Phenotypic and genotypic features of Danish patients with CHH 
Of the 41 patients, 16 had anosmia/hyposmia (as tested clinically or reported by the 
patient), 13 had normal sense of smell, and for 12 patients the data on olfaction was not 
available. Twenty-three (56%) of the patients had a history of microphallus, which is 
consistent with severe neonatal GnRH deficiency. 
Twelve (29%) of the patients were identified to have a conclusive mutation in one of the 
screened genes. The most commonly mutated gene was FGFR1, where 5 (12%) patients 
were found to have a mutation; only one of the mutations (c.289G>A p.(Gly97Ser)) had 
been previously reported in a KS patient, but the rest (c.625C>T p.(Arg209Cys), 
c.1535C>T p.(Ala512Val), c.1936C>T p.(Arg646Trp), and c.1614C>T p.(Ile538=)) 
were previously unreported. All of the missense mutations were predicted by PolyPhen-
2 to be probably damaging with a score of 1.000 (sensitivity 0.00; specificity 1.00), and 
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all were absent from the dbSNP and the NHLBI Exome Sequencing Project (EVS) 
database. The synonymous mutation c.1614C>T p.(Ile538=)) was predicted by Human 
Splicing Finder to create an exonic silencer motif and to probably affect splicing. All the 
patients with an FGFR1 mutation had a history of cryptorchidism and/or micropenis. 
Additionally, two had a cleft lip or palate. 
The second most mutations were identified in ANOS1, where three patients harbored a 
nonsense mutation (c.[309C>A;310delT] p.[(Ser103Arg);(Cys105ValfsTer13)], 
c.154_157dupAGGT p.(Cys53Ter), and c.769C>T p.(Arg257Ter)), and one patient had 
a deletion of exons 5-8 as determined by the failed amplification of just those exons in 
only that patient. Three of the patients had severe GnRH deficiency as indicated by a 
history of micropenis and/or cryptorchidism; for one patient this information was not 
available. Additionally, three patients had anosmia, and information on olfaction was 
unavailable for one patient. 
One homozygous GNRHR mutation (c.785G>A p.(Arg262Gln)) was identified in an 
nHH patient who had reversal of CHH before the age of 32 years but presented with late-
onset hypogonadism at the age of 60 years. Details of this case have been previously 
reported (Tommiska et al. 2013b). In addition, the same p.(Arg262Gln) mutation was 
identified as heterozygous in three patients, and another mutation (c.317A>G 
p.(Gln106Arg)) was found as heterozygous in one patient. 
Two patients with CHARGE-like phenotypic features were also screened for mutations 
in CHD7, and both were found to harbor a mutation in this gene. One patient had an 
esophagotracheal fistula, a bilateral cleft lip and palate, anosmia, deafness in the left ear, 
and partial hearing loss in the right ear, and he was found to have the frameshift mutation 
c.7832_7841del p.(Lys2611MetfsTer25). The other patient had syndactyly and hearing 
loss, and a mutation (c.2443-2A>C) in a conserved acceptor splice site, predicted by 
Human Splicing Finder to disrupt the normal splicing of the CHD7 mRNA. Neither of 
these mutations has been reported in the CHD7 mutation database 
(https://molgenis51.gcc.rug.nl/menu/main/home). Both patients had a history of 
micropenis and cryptorchidism. 
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One heterozygous PROK2 mutation, c.163delA p.(Ile55fsTer1), was identified in a KS 
patient, and one heterozygous TAC3 variant, c.1A>T, which changes the start codon 
ATG to TTG (coding for leucine), was identified in the KS patient with the p.(Gly97Ser) 
FGFR1 mutation. The TAC3 variant may result in deletion of the first three amino acids 
of the protein, as the next codon for methionine is found at the fourth amino acid position. 
No biallelic mutations were found in PROK2 or TAC3. No mutations in FGF8, PROKR2, 
TACR3, or KISS1R were found in the Danish CHH patients. 
The mutations identified in the Danish HH patients and their phenotypic features are 
summarized in table 4.
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5.4 SEMA3A and SEMA7A mutations identified in Finnish CHH patients 
Mutation screening of SEMA3A revealed three heterozygous missense mutations 
(c.1303G>A p.(Val435Ile), c.458A>G p.(Asn153Ser), and c.1253A>G p.(Asn418Ser)) 
in three KS patients (table 5). The patient with the p.(Asn418Ser) mutation had a 
previously identified mutation in FGFR1 (c.1305_1306dupAT p.(Ser436Tyrfs*3), as 
did the patient with the p.(Asn153Ser) mutation, who had the nonsense mutation 
c.1825C>T p.(Arg609*) in FGFR1. The third patient was not found to have any 
mutations in the previously screened KS genes (ANOS1, FGFR1, FGF8, PROK2, 
PROKR2, CHD7, WDR11, or NELF). All of the identified SEMA3A mutations were 
reported in the Exome Variant Server database. Minor allele frequencies in the European 
American population were 0.03% for the Asn418Ser mutation, 0.5% for the Asn153Ser 
mutation, and 1.4% for the Val435Ile mutation. All three mutations are located in the 
sema domain of SEMA3A protein (Figure 12a).  
Mutation screening of SEMA7A revealed two heterozygous missense variants in one 
patient with nHH (c.442C>T p.(Arg148Trp) and one patient with KS (c.1421G>A 
p.(Arg474Gln). Both patients also had a previously identified heterozygous mutation in 
a known CHH gene; the patient with nHH had a heterozygous nonsense mutation in 
KISS1R (c.1167C>A p.(Cys398*) and the KS patient had a splice-site-disrupting ANOS1 
mutation (g.2357_2360delAgta) at the exon 8-intron 8 boundary. The p.(Arg148Trp) 
mutation was reported once in the EVS database with a frequency of 1/12986 and was 
not present in the screened 200 healthy controls. The p.(Arg474Gln) variant was not 
reported in the EVS database, but several other amino acid substitutions had been 
reported in the same position, indicating that at least some variation is tolerated in that 
position. Both mutations are located in the conserved sema domain of the protein 
(Figure 12b). 
The variants identified in the Finnish CHH patients and the patients’ clinical 
characteristics are summarized in table 5. 
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Figure 12. The SEMA3A (A) and SEMA7A (B) variants identified in the Finnish CHH 
patients.  The protein domains are marked according to the UniProtKB database. Aa: amino acid 
position; Ig domain: immunoglobulin-like domain; Arg/Lys-rich region: basic region that is rich 
in arginine and lysine; RGD motif: arginine-glycine-aspartate motif recognized by some integrin 
receptors. 
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6. DISCUSSION 
Disorders of puberty and sex development cause considerable psychosocial stress for the 
affected individual and can have severe long-term health outcomes. Identifying the 
genetic defects behind these disorders not only increases our understanding on the 
genetic regulation of sex development and puberty but is also valuable for the treatment 
and genetic counseling of the individual patient and his/her family members. 
Unfortunately, although several genes have already been implicated in the different 
disorders of puberty and sex development, only in about 13-43% of DSD cases 
(Bashamboo & McElreavey 2015, Eggers et al. 2016) and in about 50% of CHH cases 
is a genetic cause identified (Kim 2015). Not even all patients with a clear phenotype 
that has an established monogenic cause, such as in CAIS, are found to have a causal 
mutation. The aim of this study was to identify genetic causes of defective development 
of sex and puberty. A new mechanism of CAIS was detected, as a deep intronic, 
pseudoexon-activating mutation was found in the androgen receptor gene.  
The genetic defects underlying both precocious and absent puberty were investigated in 
Danish patients. Mutations in MKRN3, a gene with a putative role in the inhibition of 
premature GnRH secretion, were confirmed to underlie GDPP in the Danish population, 
supporting the important role of mutations in this gene in precocious puberty. 
Additionally, conclusive mutations were found in 29% of the Danish CHH patients in 
the genes FGFR1, ANOS1, CHD7, and GNRHR. Finally, mutations in SEMA3A and 
SEMA7A, two promising CHH candidate genes, were found to be rare in Finnish CHH 
patients. These results are discussed in more detail in the following sections. 
6.1 New mechanisms underlying complete androgen insensitivity syndrome 
Most, but not all, CAIS patients are found to have a mutation in AR, indicating some 
cases may be caused by mutations in obligate AR cofactors or that some AR mutations 
are missed in routine genetic screenings. In this study, a deep intronic mutation in AR 
was identified to underlie CAIS in two siblings who had no mutations in the AR coding 
region or in the conserved splice sites. The mutation lies 118 bp upstream of exon 7 and 
was thus missed in a routine genetic screening focused on the coding exons and exon-
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intron boundaries of the gene. Analysis of the AR cDNA and whole-genome sequencing 
of the two patients, however, enabled the identification of the causal mutation with high 
confidence. Only one other deep intronic AR mutation, located 44 bp from exon 6, has 
been previously reported in a CAIS patient; the mutation caused reduced DHT binding, 
but the effect on mRNA splicing was not reported (Audi et al. 2010).  
AR cDNA analysis showed that the c.2450-118A>G mutation leads to the formation of 
two aberrantly spliced mRNA products at the expense of the normally spliced AR 
mRNA. Computational analysis and sequencing of the abnormal products revealed that 
the mutation creates both a novel 5’splice site (ss), where the U1 small nuclear 
ribonucleoprotein (snRNP) binds, and a new exonic splicing enhancer (ESE) motif for 
the SRSF1 protein, which is a member of the splicing activator family (Graveley 2000). 
Both the binding of the U1 snRNP and the SRSF1 allow the splicing machinery to 
recognize the sequence 84 bp upstream of the mutation as a new 3’ ss (de Conti et al. 
2012), thus leading to a situation where either an 85-bp-long pseudoexon located in 
intron 6, normally unrecognized by the splicing machinery, is activated (Sun & Chasin 
2000), or the entire intronic 202-nt long fragment between the new 3’ss and exon 7 is 
spliced into the mRNA. U1 snRNP and SRSF1 compete for binding to the overlapping 
sequence motifs, so that the two aberrant products are made in approximately equal 
amounts, while the amount of the normally spliced mRNA is significantly reduced. 
Both abnormal AR mRNAs are predicted to lead to a premature termination codon (PTC) 
after the addition of 12 novel amino acids. As the PTC is located more than 50-55 nt 
upstream of the last exon-exon boundary, it is predicted to lead to nonsense-mediated 
decay (NMD) of the mRNA (Isken & Maquat 2007). The overall amount of AR mRNA, 
however, was not lower in the patient fibroblasts than in the controls, although the 
amount of the normally spliced mRNA was significantly reduced. Notably, it has been 
shown that the half-life of some PTC-containing mRNAs can be similar to normal 
mRNAs, while some are destroyed rapidly in the cell (Trcek et al. 2013). Therefore, it is 
possible that the aberrant AR mRNAs are targeted by the NMD pathway even though 
they are detected in the patient fibroblasts. Additionally, even if the PTC-containing 
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mRNAs are translated into protein, the lack of detectable AR protein in the patient 
fibroblasts indicates that the resulting protein product is unstable, and that the low 
amount of normal AR mRNA is not sufficient to yield significant AR protein levels. 
Some DSD patients have an increased risk to develop gonadal tumors; for example, 
PAIS patients with non-scrotal gonads have a high malignancy risk and early 
gonadectomy is recommended (Hughes et al. 2006, Wünsch et al. 2012). On the other 
hand, patients with 17β-HSD3 deficiency, a similar phenotype, have an intermediate 
risk, in which case careful monitoring of the situation rather than gonadectomy is 
recommended to avoid overtreatment and to preserve endogenous hormone production 
(Wünsch et al. 2012). In this case, the molecular genetic diagnosis is an important factor 
in deciding whether gonadectomy should be performed or not (Wünsch et al. 2012). AR 
splice-site mutations have been reported in patients with PAIS (Brüggenwirth et al. 1997, 
Sammarco et al. 2000), so it seems plausible that deep intronic mutations may also 
underlie these cases. Notably, a mutation in the AR 5’UTR was recently identified as a 
novel mechanism underlying CAIS in two unrelated patients (Hornig et al. 2016), which 
further demonstrates the importance of mutations outside of the coding region to the 
pathogenesis of AIS. Therefore, AR cDNA analysis should be routinely performed in 
cases when no mutation is identified with sequencing of the genomic AR coding regions. 
6.2 MKRN3 mutations: a significant cause of GDPP in different 
populations 
The molecular genetic causes of GDPP were largely unknown until the discovery of 
MKRN3 loss-of-function mutations in several GDPP patients in 2013 (Abreu et al. 2013). 
In this study, one heterozygous missense mutation, p.(Arg345His), was identified in one 
Danish girl with GDPP, and subsequently also in her brother who had early puberty. 
This is a similar frequency (1/29=3.4%) to that reported previously for 207 girls with 
apparently sporadic GDPP (8/207=3.9%) from three different university medical centers 
(Macedo et al. 2014), although in familial cases, MKRN3 mutations may be identified in 
up to 46% of the cases (Simon et al. 2016). The mother did not carry the mutation, 
indicating the siblings had inherited it from their father, which is consistent with the 
maternal imprinting of the gene; only mutations that are inherited from the father can 
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cause the phenotype. Unfortunately, detailed information on the timing of the father’s 
puberty or DNA samples of the paternal grandparents were unavailable, but since the 
father’s puberty was described as average, he probably inherited the mutation from his 
mother. The mutation is also reported in the EVS database with low frequency (1/8600), 
which may be expected for this type of variant whose effects are only revealed if it is 
inherited from the father. Additionally, the database does not include information on the 
pubertal timing of the person carrying the mutation in the database. 
The girl’s age at puberty onset (around 6 years of age) was similar to that reported for 
other girls with MKRN3 mutations (median 6.0, range 3.0 to 7.5 years) (Abreu et al. 
2015). Although MKRN3 mutations are found in both girls and boys, they seem to affect 
girls more strongly, and the median age of puberty onset for boys carrying MKRN3 
mutations is 8.25 (range 5.9 to 9.0 years) (Abreu et al. 2015). In fact, some boys carrying 
an MKRN3 mutation are apparently unaffected (Dimitrova-Mladenova et al. 2016). The 
puberty of the boy in our family was not formally assessed, but he seems to be affected 
by the mutation as he did have very early voice break at 10.5 years of age; voice break 
usually occurs between Tanner stages G3 and G4 (Harries et al. 1997) at the median age 
of 14.0 in Danish boys (Juul et al. 2007). 
The mutation is predicted to be pathogenic by three prediction tools. It is located in the 
C3HC4 RING domain, predicted to have E3 ubiquitin ligase activity, where at least 5 
other missense mutations have been identified so far in GDPP patients (Abreu et al. 
2013, Settas et al. 2014, Simon et al. 2016, Neocleous et al. 2016). Interestingly, the 
majority of the patients with an identified MKRN3 mutation have either a nonsense 
mutation or a frameshift mutation leading to a premature stop codon, and the majority 
of the identified missense mutations are located in the C3HC4 domain or one of the C3H 
domains (Figure 13) (Abreu et al. 2015, Simsek et al. 2016). Several of the frameshift 
mutations are located in a poly-C stretch (codons for amino acids Pro160 and Pro161), 
indicating a mutational hotspot (Macedo et al. 2014, Simon et al. 2016, Dimitrova-
Mladenova et al. 2016). Due to the lack of an available bioassay, the functional effects 
of the mutations have not been assessed in vitro, but in silico modeling has predicted a 
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disrupted tertiary protein structure for some of the missense mutations (Settas et al. 2014, 
Neocleous et al. 2016). 
 
Figure 13. The MKRN3 mutation identified in this study along with other reported MKRN3 
mutations. The mutation (p.Arg345His) identified in this study is drawn inside a box with bold 
font. In addition, mutations reported in Abreu et al. 2013, Macedo et al. 2014, Schreiner et al. 
2014, Settas et al. 2014, de Vries et al. 2014, Grandone et al. 2015, Simon et al. 2016, Neocleous 
et al. 2016, and Simsek et al. 2016, are displayed in the figure. 
 
The exact function of MKRN3 is still unknown, but it is presumed to act as a suppressor 
of puberty onset based on two findings: the expression of Mkrn3 declines in the mouse 
arcuate nucleus at the onset of puberty, and the majority of the identified GDPP-causing 
mutations lead to a premature stop codon, indicating a loss of protein function (Abreu et 
al. 2013). Although MKRN3 is widely expressed in adult and fetal tissues (Jong et al. 
1999), few GDPP patients with an MKRN3 mutation have been reported to have 
additional anomalies, such as esotropia, high-arched palate, or dental abnormalities 
(Abreu et al. 2013, Macedo et al. 2014), suggesting MKRN3 function is not 
indispensable outside the HPG axis. In this study, MKRN3 was also found to be 
expressed in an adult human hypothalamic cDNA collection, suggesting that the 
hypothalamic MKRN3 function is not limited to the prepubertal inhibition of GnRH 
release. Unfortunately, as human hypothalamic samples are poorly available, the 
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potential temporal changes in MKRN3 expression at puberty could not be addressed in 
this study. MKRN3 is a zinc-finger protein that contains a C3HC4 RING domain that is 
found in most E3 ubiquitin ligases, three C3H zinc fingers which are typically found in 
ribonucleoproteins, and a Cys-His-rich motif which may bind DNA (Böhne et al. 2010, 
Abreu et al. 2015). MKRN3 is an intronless retrocopy of MKRN1, which has several 
identified functions mainly as an E3 ubiquitin ligase, for example in defense against 
virus infection, cell cycle arrest, and apoptosis, and possibly, independent of E3-ligase 
activity, as a transcriptional regulator (Böhne et al. 2010). The zinc-finger domain 
structure of MKRN3 and its similarity with MKRN1 suggest that it can participate in 
multiple cellular processes such as marking proteins for proteasomal degradation, 
modulation of protein function or localization, and transcriptional regulation (Böhne et 
al. 2010, Abreu et al. 2015). The elucidation of the exact mechanism by which MKRN3 
inhibits the HPG axis will be highly interesting and may reveal new players in the control 
of puberty onset. 
6.3 The genetic features of CHH in Denmark 
Although several genes have already been implicated in CHH, the majority of the 
patients still lack a conclusive molecular genetic diagnosis. This was also the case in 
Denmark, where a conclusive mutation underlying CHH was identified in 12 of the 41 
(29%) patients. FGFR1 mutations were the most frequent genetic cause: five (12%) 
patients had a heterozygous mutation in this gene. One of the FGFR1 mutations, 
p.(Gly97Ser), identified in a KS patient, has been reported previously in another KS 
patient who had scoliosis and hearing loss (Jarzabek et al. 2012) and more recently, in 
another patient with CHH and split-hand/foot malformation (Ohtaka et al. 2017); no such 
additional features had been reported for the Danish patient. The patient was also found 
to carry a heterozygous start-codon-disrupting mutation in TAC3, c.1A>T. The next 
possible start codon in the TAC3 gene sequence is in the fourth amino acid position, so 
this mutation may lead to the absence of the first three amino acids of the polypeptide. 
TAC3 mutations are implicated in autosomal recessice nHH (Topaloglu et al. 2009), and 
since the patient and his two sons all have KS, the FGFR1 mutation is most likely enough 
to explain the phenotype, although a contribution of the TAC3 mutation cannot be ruled 
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out. None of the other FGFR1 mutations [p.(Arg209Cys), p.(Ala512Val), 
p.(Arg646Trp), and p.(Ile538=)] have been reported previously, although a mutation 
affecting the same codon as Arg209Cys, c.626G>A p.(Arg209His), has been reported in 
a Finnish KS patient (Laitinen et al. 2011). Notably, neither the Danish nor the Finnish 
patient had additional phenotypic features. Although the functional effects of the 
mutations were not tested in vitro, the in silico predictions, the rarity of the mutations, 
and the fact that FGFR1 is an established CHH gene, indicate that they are highly 
probable causal mutations in these patients. Of note, all of the patients with an FGFR1 
mutation had a history of micropenis and/or cryptorchidism, indicating severe GnRH 
deficiency. Additionally, two had a cleft lip or palate, which is a typical finding 
associated with FGFR1 mutations. All had hyposmia or anosmia, except the patient with 
the p.(Ile538=) mutation, who had self-reported normal sense of smell. This 
demonstrates the phenotypic variation in CHH caused by FGFR1 mutations. 
The second most often mutated gene in Danish patients was ANOS1. Four patients 
(?10%) had a mutation in this gene, and all mutations are predicted to affect the protein 
product severely; three patients had a mutation leading to a premature stop codon 
[p.[(Ser103Arg);(Cys105ValfsTer13)], p.(Cys53Ter), and p.(Arg257Ter)], and one 
patient had a deletion of exons 5 to 8, as they could not be PCR-amplified from the 
patient’s genomic DNA even though the amplification from other DNA samples was 
successful at the same time. Failed amplification due to DNA degradation is unlikely 
because the other ANOS1 exons were successfully amplified from the same DNA sample 
after the amplification of exons 5-8 had failed. Consistent with the common finding of a 
severe reproductive phenotype in patients harboring ANOS1 mutations (Hu & Bouloux 
2011), three of the patients had a history of micropenis and/or cryptorchidism; for one 
patient this information was not available. In addition, three patients had anosmia as 
expected. Information on olfaction was unavailable for one patient, but his sense of smell 
is probably also affected, as invariably seems to be the case for patients with CHH caused 
by an ANOS1 mutation (Hu & Bouloux 2011). Unexpectedly, none of the patients were 
reported to have synkinesia or renal agenesis, which are typical findings in patients with 
ANOS1 mutations (Hu & Bouloux 2011, Costa-Barbosa et al. 2013). 
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Only one patient was found to have a biallelic mutation in GNRHR, the homozygous 
p.(Arg262Gln) mutation, which has been shown to partially impair the GnRH receptor 
function due to decreased signaling activity (de Roux et al. 1997). This patient has been 
reported previously (Tommiska et al. 2013b); he had presented with delayed puberty at 
16 years of age, had reversal of HH after testosterone treatment around the age of 30, 
and at 61, presented again with signs of hypogonadism. Additionally, the Arg262Gln 
mutation was identified in the heterozygous state in three patients, and a heterozygous 
p.(Gln106Arg) mutation, previously shown to cause reduced GnRH binding and 
impaired intracellular signaling, was identified in one patient. The p.(Arg262Gln) 
mutation is, together with the p.(Gln106Arg) mutation, the most commonly identified 
GNRHR defect underlying nHH, and homozygous Arg262Gln/Arg262Gln and 
Gln106Arg/Gln106Arg mutations, as well as compound heterozygous 
Arg262Gln/Gln106Arg mutations, tend to cause a mild phenotype (Brioude et al. 2010). 
Both mutations were also detected with a frequency of 1/95 in control individuals from 
The Copenhagen Puberty Study, a frequency similar to that previously reported in the 
Finnish population (Vaaralahti et al. 2011). Considering the relatively high carrier 
frequency of these mutations in the Danish population and the fact that mutations in 
GNRHR are the most common known genetic defect underlying nHH (Bianco & Kaiser 
2009), it is somewhat surprising that no other biallelic GNRHR mutations were 
identified. It is possible, however, that the phenotype caused by the Arg262Gln and 
Gln106Arg mutations is so mild that it goes undetected in some individuals who may 
only present with delayed puberty, or in some females may be brushed off as primary or 
secondary amenorrhea caused by excessive exercise or low body fat. In addition, it is 
unlikely that a second mutation in GNRHR went undetected in the four patients with a 
heterozygous mutation, as three of them had anosmia, indicating a different genetic 
cause. No other genetic causes of nHH were identified in the Danish patients, as there 
were no biallelic mutations in TAC3, TACR3, or KISS1R. GNRH1 and KISS1 were not 
screened because mutations in them are an extremely rare cause of nHH, so it is possible, 
although unlikely, that some mutations in these genes may have gone undetected.  
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CHD7 was screened in two patients who had CHARGE-like phenotypic features, and 
both were found to have a previously unreported mutation in this gene. One patient had 
a heterozygous frameshift mutation (p.(Lys2611MetfsTer25)) and several 
nonreproductive phenotypic features such as anosmia, a bilateral cleft lip and palate, an 
esophagotracheal fistula, deafness in the left ear, and partial hearing loss in the right ear. 
The other patient had a mutation in the conserved acceptor splice site of exon 7 (c.2443-
2A>C), which most probably disrupts the splice site and leads to defective splicing of 
the CHD7 mRNA; he had syndactyly and hearing loss in addition to severe CHH. CHD7 
mutations cause highly variable phenotypic features (Husu et al. 2013), and although 
they are not a very common cause of CHH, they have been shown to be enriched 
especially in patients with hearing loss or other ear anomalies (Jongmans et al. 2009, 
Costa-Barbosa et al. 2013). CHD7 screening should thus be prioritized in these kinds of 
patients to allow genetic counseling of the family. 
One patient with KS and a history of micropenis and cryptorchidism had a heterozygous 
PROK2 mutation, p.(Ile55fsTer1), which has been identified previously both in KS and 
nHH patients (Leroy et al. 2008, Pitteloud et al. 2007b). The mutation has been shown 
to cause loss-of-function in vitro, but heterozygous carriers of this mutation seem to be 
unaffected (Pitteloud et al. 2007b), so another mutation in PROK2 or PROKR2 would 
be needed to explain the phenotype. Of note, no biallelic PROK2 or PROKR2 mutations 
were found in the Danish patients, similarly as previously in Finnish patients (Laitinen 
et al. 2011). Interestingly, some PROKR2 mutations are enriched in the Maghrebian 
population: in a recent study, Sarfati et al. (2013) found PROKR2 mutations in 23.3% of 
Maghrebian KS patients but in only 5.1% of the European patients, and 
PROK2/PROKR2 mutations have been found to underlie 5-10% of KS cases in other 
studies (Bianco & Kaiser 2009, Martin et al. 2011). It may be that PROK2/PROKR2 
mutations are rarer in some populations, such as in the Danes and the Finns, although 
genetically the Danes are more closely related to other Northern Europeans than to the 
Finns (Beekman et al. 2013). It should be noted, however, that another, non-coding, 
PROK2 mutation may have gone undetected in the Danish patient, whose phenotype of 
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severe GnRH deficiency would fit with a biallelic mutation in this gene (Martin et al. 
2011).  
Mutations in the genes currently implicated in CHH can be found in approximately 50% 
of the patients (Kim 2015). It should be noted, however, that this figure also includes 
genes and variants whose contribution to the disease pathogenesis has not been shown 
conclusively. In this study, we focused on the genes that are the most relevant in a clinical 
setting, and identified a conclusive mutation in 29% of the patients. Not all genes 
implicated in CHH, such as HS6ST1, SEMA3A, WDR11, or NSMF, were screened, but 
as the contribution of variants in these genes to the pathogenesis of CHH is still unclear, 
they would not be of much value for example in the genetic counseling of the patients. 
Notably, although di -or oligogenicity has been suggested in CHH, (Pitteloud et al. 
2007a, Sykiotis et al. 2010), no evidence of oligogenicity was found in this patient series, 
which may largely be explained by the fact that the genes whose relevance to CHH is 
still uncertain were left unscreened.  
6.4 Current knowledge on the involvement of SEMA3A and SEMA7A 
mutations in CHH pathogenesis 
SEMA3A and SEMA7A are very promising candidate genes for Kallmann syndrome and 
normosmic HH, respectively. To elucidate the contribution of mutations in these genes 
to the pathogenesis of CHH in Finland, they were screened in 50 patients with CHH. All 
in all, only few variants were found, discussed in more detail in the following sections. 
6.4.1 The role of SEMA3A mutations in CHH 
In SEMA3A, three heterozygous missense variants (p.(Asn418Ser), p.(Asn153Ser), and 
p.(Val435Ile)) were identified in three KS patients. All of the variants have been reported 
in the Exome Variant Server database, and the p.(Val435Ile) and p.(Asn153Ser) variants 
have also been previously reported in KS patients by Hanchate et al. (2012). Both 
Val435Ile and Asn153Ser variants have been shown to cause loss-of-function in vitro; 
Val435Ile resulted in impaired SEMA3A secretion, whereas Asn153Ser caused reduced 
signaling activity in GN11 cells (Hanchate et al. 2012), although both are predicted to 
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be benign by PolyPhen-2. The p.(Asn418Ser) variant was not reported and thus not 
tested by Hanchate et al., but it is likewise predicted to be benign by PolyPhen-2.  
Although the functional studies showed impaired function of the p.(Val435Ile) and 
p.(Asn153Ser) variants indicating a pathogenic effect, the two variants are not very rare, 
as seen from their frequencies in the European American population in the EVS 
database; 1.4% for Val435Ile and 0.5% for Asn153Ser. The p.(Asn418Ser) variant is 
somewhat rarer with a frequency of 0.03% in the EVS database, but it seems to be 
enriched in the Finnish population where the frequency is 1.16% according to the SISu 
(Sequencing Initiative Suomi) Project database. Therefore, if the identified variants do 
have an effect on the development of the olfactory system or on the development or 
function of GnRH neurons, the effect must be very mild and the variants alone are not 
sufficient to cause the phenotype. These results are in accordance with those obtained by 
Hanchate et al. (2012). Based on the existence of the variants in databases and in healthy 
controls, and the fact that some patients had mutations in additional CHH genes, they 
suggested that monoallelic SEMA3A mutations are not sufficient to cause the KS 
phenotype. This is in contrast to the findings of Young et al. (2012), who proposed that 
the heterozygous deletion mutation in SEMA3A is sufficient to cause KS in a family with 
autosomal dominant mode of inheritance of the disorder. It may of course be argued that 
a deletion has a more drastic effect than a missense variant. It is also possible that the 
KS patients harboring the SEMA3A deletion have another, as-yet-unidentified mutation 
contributing to the phenotype. In this study, both of the patients carrying the 
p.(Asn153Ser) and p.(Asn418Ser) variants also had a previously identified truncating 
mutation in FGFR1, which in the light of current knowledge is sufficient to explain the 
patients’ phenotypes. As di-/oligogenicity has been repeatedly suggested in CHH 
patients (Pitteloud et al. 2007a, Sykiotis et al. 2010), however, it is possible that the 
identified SEMA3A variants contribute to the phenotype. The patient carrying the 
p.(Val435Ile) variant had no identified defects in the other known CHH genes, indicating 
that he most probably carriers at least one unidentified mutation underlying the disorder. 
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Interestingly, Hofmann et al (2013) reported biallelic SEMA3A mutations in a patient 
with short stature, skeletal abnormalities, a congenital heart defect, and camptodactyly. 
He had a deletion affecting the first exon of SEMA3A, inherited from the father, and a 
mutation disrupting the normal splicing of SEMA3A, inherited from the mother, together 
leading to significantly reduced expression of the gene in the patient. The patient was 
prepubertal but he had a normal sense of smell, and, inconsistent with the findings of 
Young et al (2012), the parents did not have KS, although the father had had a delayed 
pubertal growth spurt which may indicate delayed puberty (Hofmann et al. 2013). 
Therefore, the role of SEMA3A in human development still remains unclear. Of note, 
although most Sema3A-KO mouse models do not have severe developmental defects, 
the mouse phenotype reported by Behar et al. (1996) resembles that of the patient 
described by Hofmann et al., although the patient’s phenotype was less severe than 
observed in the mice (Hofmann et al. 2013). Taken together, the function of SEMA3A 
in human development requires further study. 
6.4.2 The role of SEMA7A mutations in CHH 
Only two heterozygous missense variants were identified in SEMA7A, one 
(p.(Arg148Trp)) in an nHH patient and one (p.(Arg474Gln) in a KS patient. The 
p.(Arg148Trp) variant has been reported in the EVS database with a frequency of 0.01% 
and 38/120024 chromosomes in the ExAC database, and the p.(Arg474Gln) variant is 
absent from the EVS database but is found in the ExAC database with a frequency of 
0.0075%. In addition, several other substitutions (p.(Arg474Leu), p.(Arg474Pro), and 
p.(Arg474Trp)) have been reported in the same amino acid position, suggesting that 
some variation is tolerated in that position. The frequency of the SEMA7A variants 
suggests that although they are predicted to be probably pathogenic by PolyPhen-2, they 
are most likely not alone sufficient to cause a CHH phenotype. The nHH patient carrying 
the p.(Arg148Trp) variant also has a previously identified heterozygous nonsense variant 
in KISS1R (c.(Cys389Ter)), a gene implicated in autosomal recessive nHH. The KISS1R 
variant is reported in the ExAC database with a frequency of 0.2% and has unknown 
functional significance. It is located in the last exon of the gene close to the normal 
termination codon. As the variant is located in the last exon, it is not predicted to lead to 
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nonsense-mediated decay of the mRNA but may result in a protein product that lacks the 
ten last amino acids, which may have an effect on receptor internalization and 
degradation (Pampillo et al. 2009). Whether SEMA7A and KISS1R are involved in a 
same cellular process that could be affected by the identified variants is currently 
unknown. The KS patient carrying the p.(Arg474Gln) variant has a previously identified 
splice-site disrupting mutation (g.2357_2360delAgta) in ANOS1, and his phenotypic 
features (severe HH and synkinesia) and family history (maternal uncle with KS) are 
consistent with KS caused by an ANOS1 mutation. Taken together, it seems unlikely that 
the identified SEMA7A variants have a significant contribution to the patients’ 
phenotypes.  
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
The existence of patients for whom no molecular genetic cause can be found in the 
already identified disease-associated genes, such as in some patients with CAIS or KS, 
suggests there are still new genes whose mutations underlie the phenotype in some of 
the unsolved cases. This has led to great efforts to identify new genetic defects 
underlying for example CHH by utilizing high-throughput sequencing methods, which 
hold great promise for the elucidation of the genetic basis of genetically heterogeneous 
disorders. As demonstrated in this study by the identification of a deep intronic mutation 
underlying CAIS in an already established gene, however, it is clear that sometimes the 
answers are found by taking a closer look at the non-coding regions of already well-
known disease-associated genes. The importance of mutations outside the coding 
regions of genes is being recognized more and more as our understanding of the 
regulation of gene expression increases. Whole-genome resequencing will potentially 
reveal new mutations in intronic and regulatory regions of genes already implicated in 
CHH, GDPP, and the different DSDs. Importantly, as seen in this study, older methods, 
such as cDNA analysis, should not be forgotten as they can invaluably complement the 
newer techniques.  
MKRN3 mutations are currently the most frequent known genetic cause of GDPP, and 
the identification of MKRN3 mutations both in boys and in girls in different populations 
around the world indicates MKRN3 should be screened in GDPP patients regardless of 
ethnic background or sex. Additionally, although MKRN3 mutations are more frequent 
in familial cases, they are also identified in approximately 4% of apparently sporadic 
cases. This study showed that MKRN3 mutations also underlie GDPP in Danish patients, 
although the frequency of mutations was quite low, possibly due to lack of other familial 
cases. The majority of GDPP patients still remain without an identified genetic cause, 
and the identification of the mechanism by which MKRN3 regulates pubertal onset will 
potentially reveal new candidate genes involved in GDPP. In addition, precocious 
puberty has so far not been studied systematically in Finland, and it will be interesting 
to study the genetic causes of this condition also in Finnish patients. 
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In this study, a conclusive mutation was identified in only 29% of Danish CHH patients 
with most mutations found in FGFR1 and ANOS1. One homozygous GNRHR mutation 
was associated with temporal variation in the endocrine phenotype and supports the 
notion that some, more common, GNRHR mutations may cause a milder phenotype. 
Expectedly, a CHD7 mutation was identified in two patients with CHARGE-like 
phenotypic characteristics. No biallelic PROK2 or PROKR2 mutations or evidence of 
oligogenicity were identified. These results can be utilized in prioritizing genetic testing 
of Danish CHH patients, although the more effective targeted gene panels are 
increasingly replacing the traditional Sanger-sequencing-based genetic screenings. Of 
note, causal mutations in the non-coding regions of some of the screened genes may have 
gone undetected in some patients, but mutations in genes not yet implicated in CHH 
probably underlie some of these cases.  The identification of new genetic defects 
underlying CHH remains a huge challenge due to the clinical and genetic heterogeneity 
of the disorder. The potential variable penetrance of the mutations, which has already 
been reported for established genes such as FGFR1, further increases the difficulty. The 
increased availability and employment of high-throughput sequencing techniques has 
led to the discovery of several new candidate genes involved in the pathogenesis of CHH, 
but the true challenge will be the identification of the real culprits behind the phenotype 
among all the candidates. Major efforts in the form of in vitro studies and in vivo 
modeling is still required before mutations found any one of those genes can be used for 
example in the genetic counseling of the patients carrying the mutations.  
Genes are often considered as good candidate disease genes based on mouse models that 
show phenotypic similarity to the disorder of interest. The role of SEMA3A and 
SEMA7A in the development and postnatal function of GnRH neurons has recently 
gained interest as, based on rodent models, they seem to have important functions in the 
guidance of olfactory system development, GnRH neuron migration, and relaying 
hormonal signals from the circulation to the GnRH neuron nerve terminals. Conflicting 
results from previous studies, however, have left the role of SEMA3A in human unclear. 
Of note, several other genetic-KO mice have shown a phenotype resembling KS or CHH, 
but mutations in the same genes have not been reported to cause CHH in humans. This 
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study showed that mutations in SEMA3A and SEMA7A are not a significant cause of 
CHH in Finland. Additionally, based on previous studies, SEMA3A mutations may not 
cause KS but an entirely different syndrome in humans. Therefore, the potential role of 
SEMA3A and SEMA7A in human reproduction still requires further study. 
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